diff --git "a/dev_JRCT_api/selenium3.ipynb" "b/dev_JRCT_api/selenium3.ipynb" new file mode 100644--- /dev/null +++ "b/dev_JRCT_api/selenium3.ipynb" @@ -0,0 +1,2406 @@ +{ + "cells": [ + { + "cell_type": "code", + "execution_count": 9, + "metadata": {}, + "outputs": [], + "source": [ + "from selenium import webdriver\n", + "from selenium.webdriver.common.by import By\n", + "from selenium.webdriver.support.ui import WebDriverWait\n", + "from selenium.webdriver.support import expected_conditions as EC\n", + "import csv\n", + "\n", + "\n", + "from selenium import webdriver\n", + "from selenium.webdriver.common.by import By\n", + "from selenium.webdriver.support.ui import WebDriverWait\n", + "from selenium.webdriver.support import expected_conditions as EC\n", + "import csv\n" + ] + }, + { + "cell_type": "code", + "execution_count": 10, + "metadata": {}, + "outputs": [], + "source": [ + "from selenium.common.exceptions import ElementClickInterceptedException, TimeoutException\n", + "\n", + "def fetch_clinical_trials(disease_name=\"\", freeword=\"\"):\n", + " \"\"\"\n", + " 指定された対象疾患名およびフリーワード検索に基づいてjRCTから臨床試験情報を取得します。\n", + "\n", + " Args:\n", + " disease_name (str): 対象疾患名（例: \"がん 神経膠腫 骨髄腫\"）\n", + " freeword (str): フリーワード検索（例: \"免疫療法\"）\n", + "\n", + " Returns:\n", + " list: 検索結果のリスト（[試験ID, タイトル, 対象疾患, 進捗状況, 日付, リンク]）\n", + " \"\"\"\n", + " # WebDriverを初期化\n", + " driver = webdriver.Chrome() # 必要に応じてChromeDriverを設定\n", + "\n", + " all_results = []\n", + "\n", + " try:\n", + " # jRCTの検索ページにアクセス\n", + " driver.get(\"https://jrct.niph.go.jp/search\")\n", + "\n", + " # 対象疾患名を入力\n", + " if disease_name:\n", + " disease_field = WebDriverWait(driver, 10).until(\n", + " EC.presence_of_element_located((By.ID, \"reg-plobrem-1\"))\n", + " )\n", + " disease_field.send_keys(disease_name)\n", + "\n", + " # 対象疾患名の条件を「or」に設定\n", + " condition_select = driver.find_element(By.ID, \"reg-plobrem-type\")\n", + " condition_select.find_element(By.CSS_SELECTOR, \"option[value='1']\").click()\n", + "\n", + " # フリーワード検索を入力\n", + " if freeword:\n", + " freeword_field = WebDriverWait(driver, 10).until(\n", + " EC.presence_of_element_located((By.ID, \"demo-1\"))\n", + " )\n", + " freeword_field.send_keys(freeword)\n", + "\n", + " # フリーワード検索の条件を「or」に設定\n", + " condition_select = driver.find_element(By.ID, \"others\")\n", + " condition_select.find_element(By.CSS_SELECTOR, \"option[value='1']\").click()\n", + "\n", + " # 募集中を選択\n", + " recruitment_checkbox = driver.find_element(By.ID, \"reg-recruitment-2\")\n", + " recruitment_checkbox.click()\n", + "\n", + " # 検索ボタンをクリック\n", + " try:\n", + " search_button = driver.find_element(By.NAME, \"button_type\")\n", + " driver.execute_script(\"arguments[0].scrollIntoView();\", search_button) # ボタンを画面内にスクロール\n", + " WebDriverWait(driver, 10).until(EC.element_to_be_clickable((By.NAME, \"button_type\"))).click()\n", + " except ElementClickInterceptedException:\n", + " print(\"検索ボタンがクリックできないため、JavaScriptでクリックします。\")\n", + " driver.execute_script(\"arguments[0].click();\", search_button)\n", + "\n", + " # ページネーション対応ループ\n", + " while True:\n", + " # 現在のページの結果がロードされるのを待機\n", + " WebDriverWait(driver, 10).until(\n", + " EC.presence_of_element_located((By.CSS_SELECTOR, \"table tbody tr\"))\n", + " )\n", + "\n", + " # 現在のページの結果を取得\n", + " rows = driver.find_elements(By.CSS_SELECTOR, \"table tbody tr\")\n", + " for row in rows:\n", + " columns = row.find_elements(By.TAG_NAME, \"td\")\n", + " if len(columns) > 4:\n", + " # 試験情報をリストに追加\n", + " trial_id = columns[0].text\n", + " title = columns[1].text\n", + " condition = columns[2].text\n", + " status = columns[3].text\n", + " date = columns[4].text\n", + "\n", + " # リンクを取得（エラー処理を追加）\n", + " try:\n", + " link = columns[1].find_element(By.TAG_NAME, \"a\").get_attribute(\"href\")\n", + " except Exception:\n", + " link = \"リンク取得エラー\"\n", + "\n", + " all_results.append([trial_id, title, condition, status, date, link])\n", + "\n", + " # ページネーションの確認\n", + " try:\n", + " current_page = driver.find_element(By.CSS_SELECTOR, \"ul.pagination li.active\").text\n", + " print(f\"{current_page} ページ目を処理しました。\")\n", + " except Exception:\n", + " print(\"ページネーションが存在しません。全ての結果を取得しました。\")\n", + " break\n", + "\n", + " # 次ページボタンのリストを取得\n", + " pagination_buttons = driver.find_elements(By.CSS_SELECTOR, \"ul.pagination li a\")\n", + " next_button = None\n", + " for button in pagination_buttons:\n", + " if button.text.isdigit() and int(button.text) > int(current_page):\n", + " next_button = button\n", + " break\n", + "\n", + " if next_button:\n", + " try:\n", + " driver.execute_script(\"arguments[0].scrollIntoView();\", next_button) # ボタンを画面内にスクロール\n", + " WebDriverWait(driver, 10).until(EC.element_to_be_clickable((By.LINK_TEXT, next_button.text))).click()\n", + " except ElementClickInterceptedException:\n", + " print(\"次ページボタンがクリックできないため、JavaScriptでクリックします。\")\n", + " driver.execute_script(\"arguments[0].click();\", next_button)\n", + " WebDriverWait(driver, 10).until(EC.staleness_of(rows[0])) # ページが変わるまで待機\n", + " else:\n", + " print(\"次のページはありません。全ての結果を取得しました。\")\n", + " break\n", + "\n", + " finally:\n", + " # ブラウザを閉じる\n", + " driver.quit()\n", + "\n", + " return all_results\n" + ] + }, + { + "cell_type": "code", + "execution_count": 14, + "metadata": {}, + "outputs": [], + "source": [ + "import pandas as pd\n", + "import requests\n", + "from bs4 import BeautifulSoup\n", + "\n", + "def scrape_jrct_all_details(url):\n", + " \"\"\"\n", + " 指定されたjRCT URLから必要なすべての情報を抽出します。\n", + " \"\"\"\n", + " # リクエストを送信\n", + " headers = {\n", + " \"User-Agent\": \"Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/91.0.4472.124 Safari/537.36\"\n", + " }\n", + " response = requests.get(url, headers=headers)\n", + " response.raise_for_status()\n", + " soup = BeautifulSoup(response.text, 'html.parser')\n", + "\n", + " # データ格納用辞書\n", + " data = {\"URL\": url}\n", + "\n", + " # \"研究・治験の目的\" を抽出\n", + " purpose_label = soup.find('label', text='研究・治験の目的')\n", + " if purpose_label:\n", + " purpose_td = purpose_label.find_parent('th').find_next_sibling('td')\n", + " if purpose_td:\n", + " data[\"研究・治験の目的\"] = purpose_td.text.strip()\n", + "\n", + " # 試験デザイン情報（日本語と英語）を抽出\n", + " design_labels = [\n", + " ('試験の種類', 'Study Type'),\n", + " ('無作為化', 'allocation'),\n", + " ('盲検化', 'masking'),\n", + " ('対照', 'control'),\n", + " ('割付け', 'assignment'),\n", + " ('研究目的', 'purpose')\n", + " ]\n", + " for label_jp, label_en in design_labels:\n", + " label = soup.find('label', string=lambda text: text and label_jp in text)\n", + " if label:\n", + " td_jp = label.find_parent('th').find_next_sibling('td')\n", + " td_en = td_jp.find_next_sibling('td') if td_jp else None\n", + " data[label_jp] = td_jp.text.strip() if td_jp else None\n", + " data[label_en] = td_en.text.strip() if td_en else None\n", + "\n", + " # その他の情報を抽出\n", + " details_labels = [\n", + " ('主たる選択基準', 'Inclusion Criteria'),\n", + " ('主たる除外基準', 'Exclusion Criteria'),\n", + " ('年齢下限', 'Age Minimum'),\n", + " ('年齢上限', 'Age Maximum'),\n", + " ('性別', 'Gender'),\n", + " ('中止基準', 'Discontinuation Criteria'),\n", + " ('対象疾患キーワード', 'Keyword'),\n", + " ('介入の内容', 'Intervention(s)')\n", + " ]\n", + " for label_jp, label_en in details_labels:\n", + " label = soup.find('label', string=lambda text: text and label_jp in text)\n", + " if label:\n", + " td_jp = label.find_parent('th').find_next_sibling('td')\n", + " td_en = td_jp.find_next_sibling('td') if td_jp else None\n", + " data[label_jp] = (\n", + " td_jp.decode_contents().strip().replace('
', '\\n') if td_jp else None\n", + " )\n", + " data[label_en] = (\n", + " td_en.decode_contents().strip().replace('
', '\\n') if td_en else None\n", + " )\n", + "\n", + " return data\n", + "\n", + "def create_dataframe_from_urls(urls):\n", + " \"\"\"\n", + " URLのリストを受け取り、pandas DataFrameを作成します。\n", + " \"\"\"\n", + " all_data = []\n", + "\n", + " for url in urls:\n", + " print(f\"Processing URL: {url}\")\n", + " data = scrape_jrct_all_details(url)\n", + " all_data.append(data)\n", + "\n", + " # pandas DataFrameに変換\n", + " return pd.DataFrame(all_data)\n", + "\n", + "\n", + "def extract_jrct_links(results):\n", + " \"\"\"\n", + " fetch_clinical_trialsの結果からjRCT-Noを抽出し、詳細リンクを作成する。\n", + "\n", + " Args:\n", + " results (list): fetch_clinical_trialsから得られる結果リスト\n", + "\n", + " Returns:\n", + " list: jRCTの詳細ページリンクリスト\n", + " \"\"\"\n", + " base_url = \"https://jrct.niph.go.jp/latest-detail/\"\n", + " links = []\n", + " for result in results:\n", + " if len(result) > 0:\n", + " jrct_no = result[0] # jRCT-Noは結果リストの最初の要素\n", + " links.append(base_url + jrct_no)\n", + " return links\n", + "\n", + "def reorder_columns(df):\n", + " \"\"\"\n", + " DataFrame の列を日本語の列を前半に、英語の列を後半に並び替える。\n", + " \"\"\"\n", + " # 日本語と英語の列を分ける\n", + " jp_columns = [col for col in df.columns if all(ord(c) < 128 for c in col) is False] # 非 ASCII（日本語）文字列を含む列\n", + " en_columns = [col for col in df.columns if col not in jp_columns] # 残りの列を英語と仮定\n", + "\n", + " # 日本語列 + 英語列の順序で整列\n", + " ordered_columns = jp_columns + en_columns\n", + "\n", + " # 列を並び替えた DataFrame を返す\n", + " return df[ordered_columns]" + ] + }, + { + "cell_type": "code", + "execution_count": 12, + "metadata": {}, + "outputs": [ + { + "name": "stdout", + "output_type": "stream", + "text": [ + "検索ボタンがクリックできないため、JavaScriptでクリックします。\n", + "ページネーションが存在しません。全ての結果を取得しました。\n" + ] + } + ], + "source": [ + "# WebDriverを初期化\n", + "driver = webdriver.Chrome() # 必要に応じてChromeDriverを設定\n", + "\n", + "# fetch_clinical_trialsを使って検索結果を取得\n", + "results = fetch_clinical_trials(disease_name=\"神経膠腫 骨髄腫\", freeword=\"\")" + ] + }, + { + "cell_type": "code", + "execution_count": 13, + "metadata": {}, + "outputs": [ + { + "data": { + "text/plain": [ + "[['jRCT2051240141',\n", + " '新たに診断され放射線療法を完了したH3 K27M変異を有するびまん性神経膠腫の治療のためのONC201：無作為...',\n", + " 'H3 K27M 変異を有する初発びまん性神経膠腫',\n", + " '募集中',\n", + " '令和6年11月6日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT2051240121',\n", + " '放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾロミ...',\n", + " '悪性神経膠腫',\n", + " '募集中',\n", + " '令和6年9月5日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT1031240239',\n", + " 'JCOG2303: 可及的摘出されたIDH変異型星細胞腫の術後化学放射線療法に対する待機化学放射線療法の非劣性...',\n", + " '神経膠腫',\n", + " '募集中',\n", + " '令和6年7月26日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT2041240056',\n", + " '[M23-001] 再発性又は難治性多発性骨髄腫患者を対象にABBV-383 を皮下投与する多施設共同，第1b 相，非...',\n", + " '多発性骨髄腫',\n", + " '募集中',\n", + " '令和6年10月3日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT2021240013',\n", + " 'ノバルティスが実施した過去のサバトリマブ（MBG453）の試験を完了し，サバトリマブ��継続投与によりベ...',\n", + " '多発性骨髄腫、慢性骨髄性白血病',\n", + " '募集中',\n", + " '令和6年6月27日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT2031240090',\n", + " '再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医師主導治験（ST...',\n", + " '悪性神経膠腫',\n", + " '募集中',\n", + " '令和6年6月26日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT2031240014',\n", + " '自家幹細胞移植に非適応又は初回治療として自家幹細胞移植を予定していない未治療の多発性骨髄腫患者を...',\n", + " '多発性骨髄腫',\n", + " '募集中',\n", + " '令和6年9月27日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT2041240003',\n", + " '再発又は難治性の多発性骨髄腫患者を対象に、AZD0305を単剤療法又は抗がん剤との併用療法として投与した...',\n", + " '再発又は難治性の多発性骨髄腫',\n", + " '募集中',\n", + " '令和6年8月20日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT2031230660',\n", + " '再発又は難治性多発性骨髄腫患者を対象とした，単剤療法としてのCevostamab及びCevostamab+ポマリドミド...',\n", + " '多発性骨髄腫',\n", + " '募集中',\n", + " '令和6年10月10日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT2021230055',\n", + " 'CD38 を標的とする前治療を受けた再発／難治性多発性骨髄腫患者を対象とした，エルラナタマブ単剤投与と...',\n", + " '再発または難治性多発性骨髄腫',\n", + " '募集中',\n", + " '令和6年9月18日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT2061230084',\n", + " '自家幹細胞移植後の奏効が不十分な初発多発性骨髄腫（NDMM）成人患者を対象とした、idecabtagene vicleu...',\n", + " '多発性骨髄腫',\n", + " '募集中',\n", + " '令和5年12月24日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT2071230097',\n", + " '再発又は難治性の多発性骨髄腫（RRMM）患者を対象にMezigdomide（CC-92480）、ボルテゾミブ及びデキサメ...',\n", + " '再発又は難治性の多発性骨髄腫（RRMM）',\n", + " '募集中',\n", + " '令和6年2月20日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT2071230095',\n", + " '再発又は難治性の多発性骨髄腫（RRMM）患者を対象にMezigdomide（CC-92480/BMS-986348）、カルフィルゾ...',\n", + " '多発性骨髄腫',\n", + " '募集中',\n", + " '令和6年4月9日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT2011230049',\n", + " '未治療多発性骨髄腫を対象とした自家末梢血幹細胞移植後の地固め療法としてIsatuximab､Pomalidomide､Dex...',\n", + " '未治療多発性骨髄腫',\n", + " '募集中',\n", + " '令和6年11月18日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT2051230108',\n", + " '再発及び難治性の多発性骨髄腫患者を対象としたBCMA x CD3 T細胞活性化抗体CC-93269の第1相オープンラベ...',\n", + " '再発及び難治性の多発性骨髄腫',\n", + " '募集中',\n", + " '令和6年1月10日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT2051230069',\n", + " '神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全性と...',\n", + " '神経膠腫',\n", + " '募集中',\n", + " '令和5年9月14日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT2031230223',\n", + " '新たに診断された多発性骨髄腫（NDMM）患者を対象として自家幹細胞移植（ASCT）後のiberdomide維持療法...',\n", + " '多発性骨髄腫',\n", + " '募集中',\n", + " '令和5年7月13日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT2051230065',\n", + " '多発性骨髄腫患者を対象として belantamab の単剤療法と他の治療との併用療法の安全性、忍容性及び有効...',\n", + " '多発性骨髄腫',\n", + " '募集中',\n", + " '令和6年11月21日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT2031230087',\n", + " '再発又は難治性の多発性骨髄腫患者を対象としたREGN5458（抗BCMA ⅹ 抗CD3二重特異性抗体）の第I/II相FIH...',\n", + " '多発性骨髄腫',\n", + " '募集中',\n", + " '令和6年6月26日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT2032230060',\n", + " '初���IDH野生型低悪性度神経膠腫に対する交流電場腫瘍治療システムの有効性と安全性を検証する多施設共同...',\n", + " 'IDH野生型神経膠腫（グレードⅢ）（退形成性星細胞腫）',\n", + " '募集中',\n", + " '令和6年7月30日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT1070230005',\n", + " '迅速ウイルスPCR法によるウイルス感染症の早期診断',\n", + " '白血病、悪性リンパ腫、多発性骨髄腫、再生不良性貧血、骨髄異形成症候群',\n", + " '募集中',\n", + " '令和5年4月11日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT2031230009',\n", + " '先行する第I、II及びIII相試験完了後も引き続きイサツキシマブに基づく治療によるベネフィットを得てい...',\n", + " '多発性骨髄腫',\n", + " '募集中',\n", + " '令和6年2月14日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT2031230007',\n", + " 'BRAF融合遺伝子陽性の進行・再発の低悪性度神経膠腫または膵癌に対するビニメチニブの第Ⅱ相医師主導治験',\n", + " '低悪性度神経膠腫、膵癌',\n", + " '募集中',\n", + " '令和6年11月22日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT2041220125',\n", + " '抗CD38 モノクローナル抗体及びレナリドミドを含む1～3 ラインの前治療歴がある再発又は難治性多発性骨...',\n", + " '再発又は難治性多発性骨髄腫',\n", + " '募集中',\n", + " '令和6年10月16日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT2021220036',\n", + " 'MAGNETISMM-6：移植非適応の初発多発性骨髄腫患者を対象としてエルラナタマブ（PF-06863135）とダラツム...',\n", + " '多発性骨髄腫',\n", + " '募集中',\n", + " '令和5年8月5日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT2063220071',\n", + " '移植適応のある初発の多発性骨髄腫被験者を対象としたダラツムマブ，ボルテゾミブ，レナリドミド及びデ...',\n", + " '初発の多発性骨髄腫',\n", + " '募集中',\n", + " '令和6年8月29日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT2021220022',\n", + " '[M22-947] 再発又は難治性多発性骨髄腫患者を対象とした薬物治療レジメンを併用したABBV-383 の用量漸増...',\n", + " '多発性骨髄腫',\n", + " '募集中',\n", + " '令和5年3月3日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT2033220220',\n", + " 'Ciltacabtagene autoleucel の投与を受けた患者を対象とした長期追跡調査試験',\n", + " '多発性骨髄腫',\n", + " '募集中',\n", + " '令和5年10月21日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT2031220060',\n", + " '自家造血幹細胞移植後の初発多発性骨髄腫患者を対象としてエルラナタマブ（PF 06863135）をレナリドミド...',\n", + " '移植後の初発多発性骨髄腫',\n", + " '募集中',\n", + " '令和6年9月17日',\n", + " 'リンク取得エラー'],\n", + " ['jRCTs051220019',\n", + " '再発悪性神経膠腫に対するホウ素中性子捕捉療法で生じる腫瘍局所の早期反応のPETによる探索',\n", + " '標準治療後の再発悪性神経膠腫',\n", + " '募集中',\n", + " '令和6年4月5日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT2053220006',\n", + " '製品規格に適合しないIDECABTAGENE VICLEUCELを被験者に投与する拡大アクセス試験（EAP）',\n", + " '再発又は難治性の多発性骨髄腫であり，承認された添付文書に基づきide-celの投与に適格である成人被験者。',\n", + " '募集中',\n", + " '令和4年7月15日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT2031210635',\n", + " '再発又は難治性多発性骨髄腫患者を対象としてteclistamabとダラツムマブ皮下投与製剤の併用（Tec-Dara）...',\n", + " '多発性骨髄腫',\n", + " '募集中',\n", + " '令和5年4月16日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT2031210607',\n", + " '有効な治療法がない又は他の治療法が適さない再発・難治性多発性骨髄腫患者を対象としたベランタマブ マ...',\n", + " '多発性骨髄腫',\n", + " '募集中',\n", + " '令和4年8月5日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT2033210469', 'デリタクト注使用成績比較調査', '悪性神経膠腫', '募集中', '令和6年7月9日', 'リンク取得エラー'],\n", + " ['jRCTs071210084',\n", + " '未治療の高齢多発性骨髄腫に対する新規薬剤と自家移植を組み合わせたシークエンス治療を固定期間で行う...',\n", + " '多発性骨髄腫',\n", + " '募集中',\n", + " '令和6年9月6日',\n", + " 'リンク取得エラー'],\n", + " ['jRCTs071210074',\n", + " '未治療多発性骨髄腫に対するダラツムマブ、レナリドミドおよびデキサメタゾン療法に治療奏効で層別化す...',\n", + " '多発性骨髄腫',\n", + " '募集中',\n", + " '令和6年9月3日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT2031210299',\n", + " '再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験',\n", + " '再発悪性神経膠腫',\n", + " '募集中',\n", + " '令和5年1月31日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT2011210025',\n", + " '造血幹細胞移植の適応とならない初発の多発性骨髄腫患者を対象として，ボルテゾミブ，レナリドミド及び...',\n", + " '多発性骨髄腫',\n", + " '募集中',\n", + " '令和5年4月7日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT2051210043',\n", + " '再発又は難治性の多発性骨髄腫（RRMM）患者を対象にiberdomide、ダラツムマブ及びデキサメタゾン（IberD...',\n", + " '再発又は難治性の多発性骨髄腫（RRMM）',\n", + " '募集中',\n", + " '令和6年5月17日',\n", + " 'リンク取得エラー'],\n", + " ['jRCTs031200320',\n", + " 'JCOG1911: 高齢者または移植拒否若年者の未治療多発性骨髄腫患者に対するダラツムマブ＋メルファラン＋...',\n", + " '多発性骨髄腫',\n", + " '募集中',\n", + " '令和6年7月23日',\n", + " 'リンク取得エラー'],\n", + " ['jRCT2033200278',\n", + " 'MMG49 抗原陽性の再発・難治性多発性骨髄腫患者を対象に OPC-415 の安全性及び有効性を検討する，多施設...',\n", + " '多発性骨髄腫',\n", + " '募集中',\n", + " '令和4年11月26日',\n", + " 'リンク取得エラー'],\n", + " ['jRCTs071190010',\n", + " '悪性神経膠腫に対する高圧酸素療法、メマンチン塩酸塩併用放射線化学治療：第Ⅲ相ランダム化比較試験',\n", + " 'WHO (World Health Organization)分類2016のグレードⅢ～Ⅳに分類される悪性神経膠腫',\n", + " '募集中',\n", + " '令和6年7月11日',\n", + " 'リンク取得エラー'],\n", + " ['jRCTs021180010',\n", + " '塩酸ニムスチン(ACNU)を用いたconvection enhanced delivery法とテモゾロミド(TMZ)内服による脊髄再発神...',\n", + " '再発脊髄悪性神経膠腫',\n", + " '募集中',\n", + " '令和3年6月9日',\n", + " 'リンク取得エラー'],\n", + " ['jRCTs061180085',\n", + " '初発悪性神経膠腫に対する手術、術後放射線治療およびTemozolomide併用の標準治療と、それにWT1-W10ペプ...',\n", + " '初発悪性神経膠腫',\n", + " '募集中',\n", + " '令和3年11月25日',\n", + " 'リンク取得エラー'],\n", + " ['jRCTs031180170',\n", + " '初発悪性神経膠腫に対するVEGFR1/2ペプチドワクチンの第I/II相臨床試験',\n", + " '悪性神経膠腫',\n", + " '募集中',\n", + " '令和4年12月19日',\n", + " 'リンク取得エラー']]" + ] + }, + "execution_count": 13, + "metadata": {}, + "output_type": "execute_result" + } + ], + "source": [ + "results" + ] + }, + { + "cell_type": "code", + "execution_count": 15, + "metadata": {}, + "outputs": [ + { + "name": "stdout", + "output_type": "stream", + "text": [ + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2051240141\n" + ] + }, + { + "name": "stderr", + "output_type": "stream", + "text": [ + "/var/folders/xj/t9whz9_x5g309fn84ql50wrm0000gn/T/ipykernel_79232/2361888799.py:21: DeprecationWarning: The 'text' argument to find()-type methods is deprecated. Use 'string' instead.\n", + " purpose_label = soup.find('label', text='研究・治験の目的')\n" + ] + }, + { + "name": "stdout", + "output_type": "stream", + "text": [ + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2051240121\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT1031240239\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2041240056\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2021240013\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031240090\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031240014\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2041240003\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031230660\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2021230055\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2061230084\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2071230097\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2071230095\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2011230049\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2051230108\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2051230069\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031230223\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2051230065\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031230087\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2032230060\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT1070230005\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031230009\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031230007\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2041220125\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2021220036\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2063220071\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2021220022\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2033220220\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031220060\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs051220019\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2053220006\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031210635\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031210607\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2033210469\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs071210084\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs071210074\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031210299\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2011210025\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2051210043\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs031200320\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2033200278\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs071190010\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs021180010\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs061180085\n", + "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs031180170\n" + ] + } + ], + "source": [ + " # jRCT詳細リンクを作成\n", + "jrct_links = extract_jrct_links(results)\n", + "\n", + " # 詳細リンクからデータフレームを作成\n", + "df = create_dataframe_from_urls(jrct_links)" + ] + }, + { + "cell_type": "code", + "execution_count": 16, + "metadata": {}, + "outputs": [], + "source": [ + "# 整列後の DataFrame を作成\n", + "sorted_df = reorder_columns(df)" + ] + }, + { + "cell_type": "code", + "execution_count": 17, + "metadata": {}, + "outputs": [ + { + "name": "stderr", + "output_type": "stream", + "text": [ + "/var/folders/xj/t9whz9_x5g309fn84ql50wrm0000gn/T/ipykernel_79232/2325933109.py:1: SettingWithCopyWarning: \n", + "A value is trying to be set on a copy of a slice from a DataFrame.\n", + "Try using .loc[row_indexer,col_indexer] = value instead\n", + "\n", + "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n", + " sorted_df['JRCT ID'] = [result[0] for result in results]\n", + "/var/folders/xj/t9whz9_x5g309fn84ql50wrm0000gn/T/ipykernel_79232/2325933109.py:2: SettingWithCopyWarning: \n", + "A value is trying to be set on a copy of a slice from a DataFrame.\n", + "Try using .loc[row_indexer,col_indexer] = value instead\n", + "\n", + "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n", + " sorted_df['Title'] = [result[1] for result in results]\n" + ] + } + ], + "source": [ + "sorted_df['JRCT ID'] = [result[0] for result in results]\n", + "sorted_df['Title'] = [result[1] for result in results]" + ] + }, + { + "cell_type": "code", + "execution_count": 18, + "metadata": {}, + "outputs": [], + "source": [ + "new_order = [\"JRCT ID\", \"Title\"] + [col for col in sorted_df.columns if col not in [\"JRCT ID\", \"Title\"]]" + ] + }, + { + "cell_type": "code", + "execution_count": 19, + "metadata": {}, + "outputs": [], + "source": [ + "sorted_df = sorted_df[new_order]" + ] + }, + { + "cell_type": "code", + "execution_count": 20, + "metadata": {}, + "outputs": [ + { + "data": { + "text/html": [ + "
\n", + "\n", + "\n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + " \n", + "
JRCT IDTitle研究・治験の目的無作為化盲検化対照割付け研究目的主たる選択基準主たる除外基準...purposeInclusion CriteriaExclusion CriteriaAge MinimumAge MaximumGenderDiscontinuation CriteriaKeywordIntervention(s)Study Type
0jRCT2051240141新たに診断され放射線療法を完了したH3 K27M変異を有するびまん性神経膠腫の治療のためのO...H3 K27M変異びまん性神経膠腫を有する被験者を対象に、放射線療法後に投与されたONC20...無作為化比較二重盲検プラセボ対照並行群間比較治療1.\\t治験の手順を理解し、（被験者又は法定代理人による）書面によるインフォームドコンセント...1.\\t原発性脊椎腫瘍。\\n\\r\\n2.\\tびまん性内在性橋神経膠腫（DIPG）。DIPGは......treatment purpose1. Able to understand the study procedures and...1. Primary spinal tumor.\\n\\r\\n2. Diffuse intri...No limitNo limitNoneParticipants will be randomized at baseline in...NaN
1jRCT2051240121放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾ...放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの...無作為化比較非盲検実薬（治療）対照並行群間比較治療以下の基準をすべて満たす必要がある<br>\\r\\n‐生検によって、以下に示す2016 年WH...以下の基準のいずれかに該当する場合、本治験へ参加できない。\\n\\r\\n‐びまん性橋膠腫（di......treatment purposeSubjects required to meet all the folloiwng cr...Patients who meets any of the following criter...No limit21age old notNoneDrug: Abemaciclib\\n\\r\\nAdministered orally\\n\\r...NaN
2jRCT1031240239JCOG2303: 可及的摘出されたIDH変異型星細胞腫の術後化学放射線療法に対する待機化学...手術で可及的摘出（90%以上の摘出）されたIDH変異型星細胞腫Grade 3を��象に、標準治...無作為化比較非盲検実薬（治療）対照並行群間比較治療一次登録適格規準<br>\\r\\n(1)　登録前に実施した最新の手術時の術中迅速病理診断もしく...(1)　活動性の重複がんを有する（同時性重複がん/多発がんおよび無病期間が2年以内の異時性重......treatment purposeThe first registration criteria\\n\\r\\n(1) The m...(1) Synchronous or metachronous (within 2 year...18age old overNo limitBothNoneGroup A: Standard treatment group [Adjuvant ch...Interventional
3jRCT2041240056[M23-001] 再発性又は難治性多発性骨髄腫患者を対象にABBV-383 を皮下投与する...再発又は難治性（R/R）MMの成人患者を対象にABBV-383の安全性及び薬物動態を検討する。単一群非盲検非対照単群比較治療米国東海岸がん臨床試験グループ（ECOG）のパフォーマンススコアが2以下<br>\\r\\n3～...B細胞成熟抗原（BCMA）xCD3二重特異性抗体の投与歴がある。\\n...treatment purposeEastern Cooperative Oncology Group (ECOG) perf...Received B-cell maturation antigen (BCMA)xCD3 ...18age old overNo limitNoneExperimental: ABBV-383 Dose A\\n\\r\\nParticipant...NaN
4jRCT2021240013ノバルティスが実施した過去のサバトリマブ（MBG453）の試験を完了し，サバトリマブの継続投...重篤な有害事象（SAE）及び有害事象（AE）を含めて，安全性を評価すること単一群非盲検非対照単群比較治療- 治験依頼者が実施するサバトリマブの試験に登録されて，サバトリマブの投与を受けており，なお...- 親試験でサバトリマブの投与を受けていないコホート又は投与群の患者。\\n\\r\\n- 許容で......treatment purpose- Participant is currently enrolled in a Novar...- Participants in cohorts or treatment groups ...18age old overNo limitBothNoneSabatolimab (MBG453): Solution for intravenous...NaN
5jRCT2031240090再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医...再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis（N4-methyl...無作為化比較非盲検無治療対照/標準治療対照並行群間比較治療1）\\t登録前直近の病理診断により組織学的にWHO2021に基づく悪性神経膠腫（膠芽腫または...1）\\t登録前2年以内の他の悪性腫瘍の既往または合併を有する。ただし局所治療により治癒と判断......treatment purpose1) Histologically diagnosed as high grade glio...1) Have a history or merger of other malignanc...18age old over75age old underBothNoneglioblastoma, grade3/4 astrocytoma, grade3 oli...Group A: BPC Therapy\\n\\r\\nDepending on the pat...NaN
6jRCT2031240014自家幹細胞移植に非適応又は初回治療として自家幹細胞移植を予定していない未治療の多発性骨髄腫患...本研究の目的は，teclistamabとダラツムマブ及びレナリドミドの併用（Tec-DR）並...無作為化比較非盲検実薬（治療）対照並行群間比較治療・国際骨髄腫作業部会（IMWG）診断規準に従って多発性骨髄腫の診断を受けている。<br>\\r...・多発性骨髄腫又はくすぶり型骨髄腫に対して，短期的コルチコステロイド投与\\n\\r\\n（デキサ......treatment purpose'- Have a diagnosis of multiple myeloma accord...- Received any prior therapy for multiple myel...18age old overNo limitBothNoneTeclistamab-Teclistamab, Daratumumab SC, Lenal...NaN
7jRCT2041240003再発又は難治性の多発性骨髄腫患者を対象に、AZD0305を単剤療法又は抗がん剤との併用療法と...Treatment単一群非盲検非対照単群比較治療- 18 歳以上又は治験が実施される管轄区域における同意の法定年齢以上の方。<br>\\n\\n...- 多発性骨髄腫の中枢神経系への浸潤を示す臨床徴候が認められる方。\\n\\n\\n\\r\\n- 慢......treatment purpose- Participants must be at least 18 years of ag...- Participants exhibiting clinical signs of ce...18age old overNo limitBothNoneAZD0305 IV every 3 weeks\\nNaN
8jRCT2031230660再発又は難治性多発性骨髄腫患者を対象とした，単剤療法としてのCevostamab及びCevo...本試験は、再発または難治性の多発性骨髄腫（R/R MM）患者を対象に、Cevostamab単...非無作為化比較非盲検非対照並行群間比較治療・過去に1回以上の前治療歴を有する、再発・難治性多発性骨髄腫患者<br>\\r\\n・Easte...・治験実施計画書に規定された入院及び活動制限を遵守できない。\\n\\r\\n・同種幹細胞移植（S......treatment purpose-Participants with R/R MM who have received at...-Inability to comply with protocol-mandated ho...18age old overNo limitBothNonecevostamab: Cevostamab will be administered in...NaN
9jRCT2021230055CD38 を標的とする前治療を受けた再発／難治性多発性骨髄腫患者を対象とした，エルラナタマブ...再発または難治性多発性骨髄腫患者を対象に，エルラナタマブ単剤投与の有効性，安全性等を標準療法...無作為化比較非盲検実薬（治療）対照並行群間比較治療・IMWG規準で定義される多発性骨髄腫と診断を受け，過去に抗CD38抗体およびレナリドミドを...・くすぶり型多発性骨髄腫を有する患者\\n\\r\\n・形質細胞白血病を有する患者\\n\\r\\n・ア......treatment purpose* Prior diagnosis of multiple myeloma as defin...* Smoldering multiple myeloma.\\n\\r\\n* Plasma c...18age old overNo limitBothNoneDrug: Elranatamab\\n\\r\\nElranatamab will be adm...NaN
10jRCT2061230084自家幹細胞移植後の奏効が不十分な初発多発性骨髄腫（NDMM）成人患者を対象とした、ideca...自家幹細胞移植後の奏効が不十分なNDMM成人患者を対象に、ide-cel + LEN維持療法...無作為化比較非盲検実薬（治療）対照並行群間比較治療・導入療法後に大量化学療法及びASCTを受けたが、その後地固め療法又は維持療法を受けていない...・中枢神経系（CNS）に骨髄腫病変を有する又は既往歴のある治験参加者\\n\\r\\n・非分泌型M......treatment purpose-Participants aged &gt;=18 with Newly Diagnose...-Participant with known central nervous system...18age old overNo limitBothNoneArmA\\n\\r\\nBiological: idecabtagene vicleucel\\n...NaN
11jRCT2071230097再発又は難治性の多発性骨髄腫（RRMM）患者を対象にMezigdomide（CC-92480...再発又は難治性多発性骨髄腫（RRMM）被験者を対象にmezigdomide（CC-92480...無作為化比較非盲検実薬（治療）対照並行群間比較治療1. 多発性骨髄腫の診断が記録されており、以下のいずれかの定義を満たす測定可能病変を有する被...1. プロテアソーム阻害剤の投与期間中又は最終投与後60日以内に病勢進行が確認された被験者。......treatment purpose1. Participant has documented diagnosis of mul...1. Participant has had progression during trea...18age old overNo limitBothNone[Japan safety lead-in cohort]\\n\\r\\nMezigdomide...NaN
12jRCT2071230095再発又は難治性の多発性骨髄腫（RRMM）患者を対象にMezigdomide（CC-92480...再発又は難治性多発性骨髄腫（RRMM）治験参加者を対象にmezigdomide、カルフィルゾ...無作為化比較非盲検実薬（治療）対照単群比較治療多発性骨髄腫の診断が記録されており、測定可能病変を有する。<br>\\r\\n1レジメン以上の抗...Mezigdomide又はカルフィルゾミブによる前治療歴を有する治験参加者。\\n\\r\\n前治......treatment purposeParticipant has documented diagnosis of Multip...Participant who has had prior treatment with m...18age old overNo limitBothNoneArm A: Mezigdomide, Carfilzomib and Dexamethas...NaN
13jRCT2011230049未治療多発性骨髄腫を対象とした自家末梢血幹細胞移植後の地固め療法としてIsatuximab､...未治療多発性骨髄腫を対象とした自家末梢血幹細胞移植後の地固め療法としてのIsatuximab...単一群非盲検非対照単群比較治療1)同意取得時の年齢が20歳以上、70歳未満の患者（性別及び入院・外来を問わず）<br>\\r...1)アミロイドーシスによる症状があり、アミロイド沈着が組織学的に証明された症例\\n\\r\\n2......treatment purpose1)Patients aged between 20 and less than 70 up...1) Patients with symptoms due to amyloidosis a...20age old over70age old notBothNoneStudy treatment,Autologous Peripheral Blood St...NaN
14jRCT2051230108再発及び難治性の多発性骨髄腫患者を対象としたBCMA x CD3 T細胞活性化抗体CC-93...再発及び難治性の多発性骨髄腫の被験者でのCC-93269の安全性及び忍容性を評価する。単一群非盲検非対照単群比較治療・再発及び難治性の多発性骨髄腫の病歴があること。<br>\\r\\n・米国東海岸癌臨床試験グルー...・症候性の中枢神経系浸潤を有する多発性骨髄腫患者\\n\\r\\n・CC-93269投与開始前3ヵ......treatment purpose-History of multiple myeloma with relapsed and...-Symptomatic central nervous system involvemen...18age old overNo limitBothNoneCC-93269NaN
15jRCT2051230069神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全...神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全...単一群非盲検非対照単群比較治療＜コホート1＞以下のすべての項⽬を満たすものとする。<br>\\r\\n1）摘出術⼜は⽣検の病理...＜コホート1、コホート2共通＞\\n\\r\\n1） 活動性の重複がんを有する（同時性重複がん/多......treatment purpose&lt;Cohort 1&gt;\\n\\r\\n All of the following it...&lt;Common to Cohort 1 and Cohort 2&gt;\\n\\r\\n1...18age old overNo limitBothNone&lt;cohort1&gt;\\n\\r\\nLomustine 130 mg/m2 orall...NaN
16jRCT2031230223新たに診断された多発性骨髄腫（NDMM）患者を対象として自家幹細胞移植（ASCT）後のibe...新たに診断された多発性骨髄腫（NDMM）患者を対象として、自家幹細胞移植（ASCT）後のレナ...無作為化比較非盲検実薬（治療）対照並行群間比較治療-症候性多発性骨髄腫(MM)の確定診断を受けてい���<br>\\r\\n- 米国東海岸癌臨床試験グ...-地固め療法の有無に関わらずASCT後にprogressive disease又は臨床的再発......treatment purpose- Confirmed diagnosis of symptomatic multiple ...- Progressive disease or clinical relapse (as ...18age old overNo limitBothNoneArm A1: Iberdomide Dose 1\\n\\r\\nArm A2: Iberdom...NaN
17jRCT2051230065多発性骨髄腫患者を対象として belantamab の単剤療法と他の治療との併用療法の安全性...パート 1：3ライン以上の前治療を受けた（4L+）再発・難治性多発性骨髄腫（RRMM）患者を...無作為化比較非盲検実薬（治療）対照並行群間比較治療• 署名時の年齢が18歳以上、又は各国における同意可能な法定年齢以上である被験者。<br>\\...• 原発性ALアミロイドーシス、活動性POEMS症候群、原発性形質細胞性白血病と診断されてい......treatment purpose-Participants at the time of signing the Infor...- Diagnosis of primary Amyloid Light chain (AL...18age old overNo limitBothNonePart1:\\n\\r\\nDrug: Belantamab\\n\\r\\nDrug: Belant...NaN
18jRCT2031230087再発又は難治性の多発性骨髄腫患者を対象としたREGN5458（抗BCMA ⅹ 抗CD3二重特...・本治験の第I相用量漸増パート：再発又は難治性MM患者を対象に、単剤療法としてのREGN54...非無作為化比較非盲検非対照単群比較治療・米国東海岸がん臨床試験グループ（ECOG）パフォーマンスステータスが1以下の被験者<br>...・形質細胞白血病、原発性全身性軽鎖アミロイドーシス（骨髄腫関連アミロイドーシスを除く）、ヴァ......treatment purpose- Eastern Cooperative Oncology Group (ECOG) pe...- Diagnosis of plasma cell leukemia, primary s...18age old overNo limitBothNoneDrug: REGN5458 administered by intravenous (IV...NaN
19jRCT2032230060初発IDH野生型低悪性度神経膠腫に対する交流電場腫瘍治療システムの有効性と安全性を検証する多...初発IDH野生型低悪性度神経膠腫を対象に、放射線化学療法後のテモゾロミド維持療法期における交...単一群非盲検非対照単群比較治療1）腫瘍摘出術または生検術を行い、IDH 野生型神経膠腫（グレードⅢ）（退形成性星細胞腫）＊...以下のいずれかの条件に該当する者は対象としない。\\n\\r\\n1) 活動性の重複がんを有する（......treatment purposeAt the time of enrollment, patients will be in...Any of the following conditions shall not appl...18age old overNo limitBothNoneGliomaThe patient using the product should shave all...NaN
20jRCT1070230005迅速ウイルスPCR法によるウイルス感染症の早期診断ウイルス感染疾患が疑われる患者について、検体を採取し、本診断法により①単純ヘルペスウイルス1...ウイルス感染症が疑われるもの（造血幹細胞移植＜自家骨髄移植、自家末梢血幹細胞移植、同種骨髄移...検体採取の同意が得られない患者、試験の担当医師が不適当と判断した患者は対象として除外する。こ......Thing with suspected virus infection(limited t...The patients who judged that the patients that...No limitNo limitBothNoneLeukemia, malignant lymphoma, multiple myeloma...Observational
21jRCT2031230009先行する第I、II及びIII相試験完了後も引き続きイサツキシマブに基づく治療によるベネフィッ...本治験は、先行する第I、II及びIII相試験完了後も引き続きイサツキシマブに基づく治療による...単一群非盲検非対照単群比較治療- 同意書への署名の時点で18歳以上（又は治験を実施する管轄区域の同意の法定成人年齢以上）の...以下のいずれかの基準に該当する場合は、治験の組入れ対象から除外する。\\n\\r\\n- 先行試験......treatment purpose- Participant must be &gt;=18 years of age (or...Participants are excluded from the study if an...18age old overNo limitBothNoneDrug: Isatuximab IV (SAR650984)\\n\\r\\n Pharmace...NaN
22jRCT2031230007BRAF融合遺伝子陽性の進行・再発の低悪性度神経膠腫または膵癌に対するビニメチニブの第Ⅱ相医...BRAF融合遺伝子または遺伝子再構成陽性の切除不能または再発の低悪性度神経膠腫（コホート A...単一群非盲検非対照単群比較治療コホートA、コホートB共通の適格規準<br>\\r\\n1）\\t保険診療下で行われているNGSを...1）\\t活動性の重複がんを有する（ただし、次の①～③は除外しない：①完全切除された以下のがん......treatment purposeInclusion criteria for both cohort A and B\\n\\r...1) Active double primary cancer (but not (1)-(...12age old overNo limitBothNoneBRAF fusion gene, BRAF rearrangement, low-grad...Binimetinib is administered 45 mg orally, twic...NaN
23jRCT2041220125抗CD38 モノクローナル抗体及びレナリドミドを含む1～3 ラインの前治療歴がある再発又は難...本試験の目的は，teclistamabの有効性をPVd/Kdと比較することである。無作為化比較非盲検実薬（治療）対照並行群間比較治療・以下の基準により定義される多発性骨髄腫が診断されている。<br>\\r\\na. 国際骨髄腫作...・B 細胞成熟抗原（BCMA）を標的とする前治療を受けていた。\\n\\r\\n・以下が認められる......treatment purpose- Documented diagnosis of multiple myeloma as ...- Received any prior B cell maturation antigen...18age old overNo limitBothNoneTeclistamab: Participants will receive teclist...NaN
24jRCT2021220036MAGNETISMM-6：移植非適応の初発多発性骨髄腫患者を対象としてエルラナタマブ（PF-...本治験のパート 1 では多発性骨髄腫（MM）患者を対象として，エルラナタマブとダラツムマブお...無作為化比較非盲検実薬（治療）対照要因分析治療・IMWG規準(Rajkumar et al., 2014)で定義される多発性骨髄腫と診断を...・くすぶり型多発性骨髄腫\\n\\r\\n・意義不明の単クローン性免疫グロブリン血症\\n\\r\\n・......treatment purposeInclusion Criteria:\\n\\r\\n*Diagnosis of multipl...Exclusion Criteria:\\n\\r\\n*Smoldering Multiple ...18age old overNo limitBothNonePart 1 Dose Level 1:Elranatamab, Daratumumab, ...NaN
25jRCT2063220071移植適応のある初発の多発性骨髄腫被験者を対象としたダラツムマブ，ボルテゾミブ，レナリドミド及...無増悪生存期間（PFS）及び持続的微小残存病変（MRD）陰性complete respons...無作為化比較非盲検実薬（治療）対照並行群間比較治療・IMWGの診断基準に従いNDMMと確定診断されており，初期治療計画の一部として大量療法及び...・標的を問わずCAR-T療法による前治療。\\n\\r\\n・BCMAを標的とする全ての治療歴。\\......treatment purpose- Participants with documented NDMM accordin...- Prior treatment with CAR-T therapy directed ...18age old overNo limitBothNone- Arm A (DVRd Induction + ASCT + DVRd Consolid...NaN
26jRCT2021220022[M22-947] 再発又は難治性多発性骨髄腫患者を対象とした薬物治療レジメンを併用したAB...再発又は難治性多発性骨髄腫患者を対象にポマリドミド-デキサメタソン（Pd），レナリドミド-デ...単一群非盲検非対照単群比較治療- 米国東海岸がん臨床試験グループ（ECOG）performanceが2以下である。<br>...- 治験薬の初回投与前12 週間以内に末梢血自家幹細胞移植を受けている，又は治験薬の初回投与......treatment purpose- Eastern Cooperative Oncology Group (ECOG) pe...- Received a peripheral autologous stem cell t...20age old overNo limitBothNoneParticipants will receive intravenous (IV) ABB...NaN
27jRCT2033220220Ciltacabtagene autoleucel の投与を受けた患者を対象とした長期追跡調査試験この試験の目的は、ciltacabtagene autoleucel(Cilta-cel)投...単一群非盲検非対照単群比較その他・企業が主導（共同）して実施する臨床試験でcilta-celの投与を少なくとも1回受けた被験...なし...other- Participants who have received at least one ...N/A18age old overNo limitBothNoneCilta-cel:Participants who had received cilta-...NaN
28jRCT2031220060自家造血幹細胞移植後の初発多発性骨髄腫患者を対象としてエルラナタマブ（PF 06863135...自家造血幹細胞移植後に初発多発性骨髄腫患者を対象として，PF-06863135の単剤投与がレ...無作為化比較非盲検実薬（治療）対照並行群間比較治療選択基準:<br>\\r\\n•IMWG 規準で定義される多発性骨髄腫と診断を受けた患者。初発多...除外基準:\\n\\r\\n•形質細胞白血病\\n\\r\\n•アミロイドーシス，ワルデンシュトレームマ......treatment purposeInclusion Criteria:\\n\\r\\n*Diagnosis of MM as d...Exclusion Criteria:\\n\\r\\n*Plasma cell leukemia...18age old overNo limitBothNoneDrug: Elranatamab \\n\\r\\nBCMA-CD3 bispecific an...NaN
29jRCTs051220019再発悪性神経膠腫に対するホウ素中性子捕捉療法で生じる腫瘍局所の早期反応のPETによる探索BNCT(Boron Neutron Capture Therapy：ホウ素中性子捕捉療法)...単一群非盲検非対照単群比較その他① 悪性神経膠腫の病理組織学的診断が得られている。<br>\\r\\n② 標準治療後に再発し、ベ...① 髄腔播種を認める。\\n\\r\\n② 抗生物質、抗ウイルス薬、抗真菌薬などの静脈内投与が必要......other1. A histopathological diagnosis of malignant ...Patients with the following medical conditions...20age 0month 0week old over79age 0month 0week old underBothNoneBNCT is performed in combination with a cyclot...Interventional
30jRCT2053220006製品規格に適合しないIDECABTAGENE VICLEUCELを被験者に投与する拡大アクセ...本治験の主要目的は、不適合ide-celの安全性を評価することである。単一群非盲検非対照単群比較治療1.治験開始前に、同意説明文書の内容を理解し、自由意思により署名できる被験者及び／又はLAR...1.有効成分又は添加剤に対して過敏症のある患者。\\n\\r\\n2.担当医師の判断で、LD化学療......treatment purpose1.Subject and/or LAR must understand and volun...1. Subject has a hypersensitivity to the activ...18age old overNo limitBothNoneIn accordance with the ide-cel prescribing inf...NaN
31jRCT2031210635再発又は難治性多発性骨髄腫患者を対象としてteclistamabとダラツムマブ皮下投与製剤の...本治験の目的は，teclistamab とダラツムマブ皮下投与製剤（SC）の併用（Tec-D...無作為化比較非盲検実薬（治療）対照並行群間比較治療選択基準<br>\\r\\n‐以下の基準により定義される多発性骨髄腫が確認されている。\\n\\r\\...除外基準\\n\\r\\n‐治験薬又はその添加物に対する禁忌又は生命を脅かすアレルギー，過敏症を呈......treatment purposeInclusion Criteria:\\n\\r\\n- Documented multiple...Exclusion Criteria:\\n\\r\\n- Contraindications o...18age old overNo limitBothNoneDaratumumab\\n\\r\\nArm A: Teclistamab-daratumuma...NaN
32jRCT2031210607有効な治療法がない又は他の治療法が適さない再発・難治性多発性骨髄腫患者を対象としたベランタマ...既存の治療法でベネフィットが得られず、進行中又は実施予定の本剤の臨床試験に適格でなく、かつ適...単一群非盲検非対照単群比較治療-国際骨髄腫作業部会(IMWG)の基準[Rajkumar, 2014]に従って組織学的又は細...-同種幹細胞移植歴を有する被験者\\n\\r\\n-腎疾患、肝疾患、心血管障害、悪性腫瘍を含む、重......treatment purpose-Histologically or cytologically confirmed dia...-Prior allogenic stem cell transplant.\\n\\r\\n-A...18age old overNo limitBothNoneBelantamab mafodotin (anti-BCMA (B-cell matura...NaN
33jRCT2033210469デリタクト注使用成績比較調査使用実態下におけるデリタクト注の悪性神経膠腫患者に対する安全性及び有効性を確認することを目的...・本品投与群：登録期間内に本剤の投与を開始する全ての患者<br>\\r\\n・対照群：本品納入施...なし...-Delytact injection group : All patients who s...noneNo limitNo limitBothNoneNaN
34jRCTs071210084未治療の高齢多発性骨髄腫に対する新規薬剤と自家移植を組み合わせたシークエンス治療を固定期間で...未治療の高齢者多発性骨髄腫に対する新規薬剤と自家移植を組み合わせたシークエンス治療を固定期間...単一群非盲検非対照単群比較治療1) 登録時の年齢が66歳以上75歳以下で、fitの患者。<br>\\r\\n2) IMWG...1) くすぶり型およびIgM型の骨髄腫、孤立性形質細胞腫、形質細胞性白血病、POEMS症候......treatment purpose1) Patients who are 66 years old or older and ...1) Cases of smoldering and IgM myeloma, solita...66age old over75age old underBothNone1. Daratumumab + lenalidomide + dexamethasone ...Interventional
35jRCTs071210074未治療多発性骨髄腫に対するダラツムマブ、レナリドミドおよびデキサメタゾン療法に治療奏効で層別...未治療多発性骨髄腫に対し、ダラツムマブ、レナリドミドおよびデキサメサゾン投与による寛解導入療...単一群非盲検非対照単群比較治療1) 登録時の年齢が20歳以上65歳以下の症例。<br>\\r\\n2) IMWGの診断基準...1) くすぶり型およびIgM型の骨髄腫、孤立性形質細胞腫、形質細胞性白血病、POEMS症候......treatment purpose1) Cases in which the age at the time of regis...1) Cases of smoldering and IgM myeloma, solita...20age old over65age old underBothNone1) Induction therapy\\n\\r\\nDRD therapy 1,2 cour...Interventional
36jRCT2031210299再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び...単一群非盲検非対照単群比較治療1.\\t3ヵ月以上の生存が見込める患者<br>\\r\\n2.\\t前治療（化学療法、手術又は放射...1.\\tDay 1前の3ヵ月以内にベバシズマブ又はその他の血管内皮増殖因子（VEGF）阻害薬......treatment purpose1.\\tEstimated life expectancy &gt;= 3 months\\n...1.\\tPrior therapy with bevacizumab or other an...18age old overNo limitBothNonePatients will receive DSP-0390 orally once dai...NaN
37jRCT2011210025造血幹細胞移植の適応とならない初発の多発性骨髄腫患者を対象として，ボルテゾミブ，レナリドミド...造血幹細胞移植が適応とならない初発の多発性骨髄腫患者において，VRd 導入療法後にJNJ-6...無作為化比較非盲検実薬（治療）対照並行群間比較治療･国際骨髄腫作業部会(IMWG )診断規準によるMMの診断が確定している被験者。<br>\\r...･Myeloma Geriatric Assessmentスコアに従ったフレイル指数が2点以......treatment purpose- Documented diagnosis of multiple myeloma (MM...-Frailty index of &gt;=2 according to Myeloma ...20age old overNo limitBothNoneArm A\\n\\r\\nParticipants will receive bortezomi...NaN
38jRCT2051210043再発又は難治性の多発性骨髄腫（RRMM）患者を対象にiberdomide、ダラツムマブ及びデ...��発又は難治性の多発性骨髄腫（RRMM）患者を対象に無増悪生存期間（PFS）についてiber...無作為化比較非盲検実薬（治療）対照並行群間比較治療1. MMの診断がされており測定可能病変（以下の基準のいずれかに該当する場合と定義）を有する...1. 以下の臨床検査値異常のいずれかが認められる\\n\\r\\na. 好中球絶対数（ANC）が1......treatment purpose1. Documented diagnosis of MM and measurable d...1. Any of the following laboratory abnormaliti...18age old overNo limitBothNone[IberDd] At the First Stage, Iberdomide (CC-22...NaN
39jRCTs031200320JCOG1911: 高齢者または移植拒否若年者の未治療多発性骨髄腫患者に対するダラツムマブ＋...高齢または移植拒否若年の未治療多発性骨髄腫患者に対するダラツムマブ＋メルファラン＋プレドニゾ...無作為化比較非盲検実薬（治療）対照並行群間比較治療一次登録適格規準<br>\\r\\n（1）IMWG2014の診断規準のMyeloma defin...（1）活動性の重複がんを有する（同時性重複がん/多発がんおよび無病期間が5年以内の異時性重複......treatment purposeFirst registration criteria\\n\\r\\n(1)At leaset ...(1) Simultaneous or metachronous (within 5 yea...20age old overNo limitBothNoneInduction therapy (both arm A and arm B) D-MPB...Interventional
40jRCT2033200278MMG49 抗原陽性の再発・難治性多発性骨髄腫患者を対象に OPC-415 の安全性及び有効...【第 I 相部分】\\r\\n• 骨髄腫細胞特異的抗体（ MMG49）抗原陽性の再発・難治性のM...単一群非盲検非対照単群比較治療-同意取得時の年齢が20歳以上，80歳（第 I 相部分では75歳）以下の患者<br>\\r\\n...-次治療で造血幹細胞移植併用大量化学療法を予定している患者\\n\\r\\n-他の活動性の重複がん......treatment purpose-Patients aged between 20 and 80 (75 for the p...-Patients who are scheduled to receive high-do...20age old over80age old underBothNoneOPC-415 (up to 1X10^7cells/kg)\\n\\r\\nOn 2 days\\...NaN
41jRCTs071190010悪性神経膠腫に対する高圧酸素療法、メマンチン塩酸塩併用放射線化学治療：第Ⅲ相ランダム化比較試験悪性神経膠腫患者に対する放射線照射療法によって引き起こされる認知機能低下が、メマンチン塩酸塩...無作為化比較二重盲検プラセボ対照並行群間比較治療1.　神経放射線学的及び病理組織学的診断法を用いWHO (World Health Orga...1．試験薬に対して過敏症のある患者\\n\\r\\n2．腎機能障害のある患者\\n\\r\\n3．尿pH......treatment purposePatients with malignant glioma who are classif...1. Patients with hypersensitivity to the study...20age old overNo limitBothNonegliobalastoma, anaplastic astrocytoma,anaplast...1)Arm A: Patients randomly selected group have...Interventional
42jRCTs021180010塩酸ニムスチン(ACNU)を用いたconvection enhanced delivery法...悪性脊髄神経膠腫に対する塩酸ニムスチンを用いたconvection enhanced del...単一群非盲検無治療対照/標準治療対照単群比較治療1.\\t臨床的に脊髄再発神経膠腫と考えられる症例。放射線画像診断的には、脊髄髄内に病変を有す...1)\\t活動性の重複がんを有する\\n\\r\\n2)\\t治療が必要な髄膜炎または肺炎を合併\\n\\......treatment purpose1. Clinically considered a spinal cord recurre...1) have active duplicate cancer\\n\\r\\n2) Mergin...15age old over75age old underBothNoneSpinal cord tumorACNU delivery (0.25 mg/ml, 4ml) into the spin...Interventional
43jRCTs061180085初発悪性神経膠腫に対する手術、術後放射線治療およびTemozolomide併用の標準治療と、...初発悪性神経膠腫において手術、放射線治療およびTemozolomideを受ける、化学療法未施...非無作為化比較非盲検非対照単群比較治療悪性神経膠腫において、これから放射線療法を受ける、化学療法未施行症例に対し、WT1-W10ペ...1）コントロール不良な感染症（活動性の結核を含む）を有する患者。\\n\\r\\n2）重篤な合併症......treatment purposeMalignant glioma patients who are going to rec...1)\\tPatients with uncontrollable infectious di...18age old over80age old notBothNone1)\\tWT1-W10 peptide immunotherapy\\n\\r\\nIntrade...Interventional
44jRCTs031180170初発悪性神経膠腫に対するVEGFR1/2ペプチドワクチンの第I/II相臨床試験初発悪性神経膠腫に対するVEGFR1/2由来のHLA-A*2402拘束性エピトープペプチドを...単一群非盲検ヒストリカルコントロール単群比較治療1）悪性神経膠腫 <br>\\r\\n2）HLA型がHLA-A*2402、A*0201、A*02...1)コントロール不良な感染症を有する患者。 \\n\\r\\n2）重篤な合併症を有する患者。 \\n......treatment purpose1)malignant glioma \\n\\r\\n2) HLA-A*2402, A*0201...1) Uncontrollable severe infectious diseases. ...16age old over79age old underBothNoneMalignant gliomaSubcutaneous injection of VEGFR1 and VEGFR2 pe...Interventional
\n", + "

45 rows × 32 columns

\n", + "
" + ], + "text/plain": [ + " JRCT ID Title \\\n", + "0 jRCT2051240141 新たに診断され放射線療法を完了したH3 K27M変異を有するびまん性神経膠腫の治療のためのO... \n", + "1 jRCT2051240121 放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾ... \n", + "2 jRCT1031240239 JCOG2303: 可及的摘出されたIDH変異型星細胞腫の術後化学放射線療法に対する待機化学... \n", + "3 jRCT2041240056 [M23-001] 再発性又は難治性多発性骨髄腫患者を対象にABBV-383 を皮下投与する... \n", + "4 jRCT2021240013 ノバルティスが実施した過去のサバトリマブ（MBG453）の試験を完了し，サバトリマブの継続投... \n", + "5 jRCT2031240090 再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医... \n", + "6 jRCT2031240014 自家幹細胞移植に非適応又は初回治療として自家幹細胞移植を予定していない未治療の多発性骨髄腫患... \n", + "7 jRCT2041240003 再発又は難治性の多発性骨髄腫患者を対象に、AZD0305を単剤療法又は抗がん剤との併用療法と... \n", + "8 jRCT2031230660 再発又は難治性多発性骨髄腫患者を対象とした，単剤療法としてのCevostamab及びCevo... \n", + "9 jRCT2021230055 CD38 を標的とする前治療を受けた再発／難治性多発性骨髄腫患者を対象とした，エルラナタマブ... \n", + "10 jRCT2061230084 自家幹細胞移植後の奏効が不十分な初発多発性骨髄腫（NDMM）成人患者を対象とした、ideca... \n", + "11 jRCT2071230097 再発又は難治性の多発性骨髄腫（RRMM）患者を対象にMezigdomide（CC-92480... \n", + "12 jRCT2071230095 再発又は難治性の多発性骨髄腫（RRMM）患者を対象にMezigdomide（CC-92480... \n", + "13 jRCT2011230049 未治療多発性骨髄腫を対象とした自家末梢血幹細胞移植後の地固め療法としてIsatuximab､... \n", + "14 jRCT2051230108 再発及び難治性の多発性骨髄腫患者を対象としたBCMA x CD3 T細胞活性化抗体CC-93... \n", + "15 jRCT2051230069 神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全... \n", + "16 jRCT2031230223 新たに診断された多発性骨髄腫（NDMM）患者を対象として自家幹細胞移植（ASCT）後のibe... \n", + "17 jRCT2051230065 多発性骨髄腫患者を対象として belantamab の単剤療法と他の治療との併用療法の安全性... \n", + "18 jRCT2031230087 再発又は難治性の多発性骨髄腫患者を対象としたREGN5458（抗BCMA ⅹ 抗CD3二重特... \n", + "19 jRCT2032230060 初発IDH野生型低悪性度神経膠腫に対する交流電場腫瘍治療システムの有効性と安全性を検証する多... \n", + "20 jRCT1070230005 迅速ウイルスPCR法によるウイルス感染症の早期診断 \n", + "21 jRCT2031230009 先行する第I、II及びIII相試験完了後も引き続きイサツキシマブに基づく治療によるベネフィッ... \n", + "22 jRCT2031230007 BRAF融合遺伝子陽性の進行・再発の低悪性度神経膠腫または膵癌に対するビニメチニブの第Ⅱ相医... \n", + "23 jRCT2041220125 抗CD38 モノクローナル抗体及びレナリドミドを含む1～3 ラインの前治療歴がある再発又は難... \n", + "24 jRCT2021220036 MAGNETISMM-6：移植非適応の初発多発性骨髄腫患者を対象としてエルラナタマブ（PF-... \n", + "25 jRCT2063220071 移植適応のある初発の多発性骨髄腫被験者を対象としたダラツムマブ，ボルテゾミブ，レナリドミド及... \n", + "26 jRCT2021220022 [M22-947] 再発又は難治性多発性骨髄腫患者を対象とした薬物治療レジメンを併用したAB... \n", + "27 jRCT2033220220 Ciltacabtagene autoleucel の投与を受けた患者を対象とした長期追跡調査試験 \n", + "28 jRCT2031220060 自家造血幹細胞移植後の初発多発性骨髄腫患者を対象としてエルラナタマブ（PF 06863135... \n", + "29 jRCTs051220019 再発悪性神経膠腫に対するホウ素中性子捕捉療法で生じる腫瘍局所の早期反応のPETによる探索 \n", + "30 jRCT2053220006 製品規格に適合しないIDECABTAGENE VICLEUCELを被験者に投与する拡大アクセ... \n", + "31 jRCT2031210635 再発又は難治性多発性骨髄腫患者を対象としてteclistamabとダラツムマブ皮下投与製剤の... \n", + "32 jRCT2031210607 有効な治療法がない又は他の治療法が適さない再発・難治性多発性骨髄腫患者を対象としたベランタマ... \n", + "33 jRCT2033210469 デリタクト注使用成績比較調査 \n", + "34 jRCTs071210084 未治療の高齢多発性骨髄腫に対する新規薬剤と自家移植を組み合わせたシークエンス治療を固定期間で... \n", + "35 jRCTs071210074 未治療多発性骨髄腫に対するダラツムマブ、レナリドミドおよびデキサメタゾン療法に治療奏効で層別... \n", + "36 jRCT2031210299 再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験 \n", + "37 jRCT2011210025 造血幹細胞移植の適応とならない初発の多発性骨髄腫患者を対象として，ボルテゾミブ，レナリドミド... \n", + "38 jRCT2051210043 再発又は難治性の多発性骨髄腫（RRMM）患者を対象にiberdomide、ダラツムマブ及びデ... \n", + "39 jRCTs031200320 JCOG1911: 高齢者または移植拒否若年者の未治療多発性骨髄腫患者に対するダラツムマブ＋... \n", + "40 jRCT2033200278 MMG49 抗原陽性の再発・難治性多発性骨髄腫患者を対象に OPC-415 の安全性及び有効... \n", + "41 jRCTs071190010 悪性神経膠腫に対する高圧酸素療法、メマンチン塩酸塩併用放射線化学治療：第Ⅲ相ランダム化比較試験 \n", + "42 jRCTs021180010 塩酸ニムスチン(ACNU)を用いたconvection enhanced delivery法... \n", + "43 jRCTs061180085 初発悪性神経膠腫に対する手術、術後放射線治療およびTemozolomide併用の標準治療と、... \n", + "44 jRCTs031180170 初発悪性神経膠腫に対するVEGFR1/2ペプチドワクチンの第I/II相臨床試験 \n", + "\n", + " 研究・治験の目的 無作為化 盲検化 \\\n", + "0 H3 K27M変異びまん性神経膠腫を有する被験者を対象に、放射線療法後に投与されたONC20... 無作為化比較 二重盲検 \n", + "1 放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの... 無作為化比較 非盲検 \n", + "2 手術で可及的摘出（90%以上の摘出）されたIDH変異型星細胞腫Grade 3を対象に、標準治... 無作為化比較 非盲検 \n", + "3 再発又は難治性（R/R）MMの成人患者を対象にABBV-383の安全性及び薬物動態を検討する。 単一群 非盲検 \n", + "4 重篤な有害事象（SAE）及び有害事象（AE）を含めて，安全性を評価すること 単一群 非盲検 \n", + "5 再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis（N4-methyl... 無作為化比較 非盲検 \n", + "6 本研究の目的は，teclistamabとダラツムマブ及びレナリドミドの併用（Tec-DR）並... 無作為化比較 非盲検 \n", + "7 Treatment 単一群 非盲検 \n", + "8 本試験は、再発または難治性の多発性骨髄腫（R/R MM）患者を対象に、Cevostamab単... 非無作為化比較 非盲検 \n", + "9 再発または難治性多発性骨髄腫患者を対象に，エルラナタマブ単剤投与の有効性，安全性等を標準療法... 無作為化比較 非盲検 \n", + "10 自家幹細胞移植後の奏効が不十分なNDMM成人患者を対象に、ide-cel + LEN維持療法... 無作為化比較 非盲検 \n", + "11 再発又は難治性多発性骨髄腫（RRMM）被験者を対象にmezigdomide（CC-92480... 無作為化比較 非盲検 \n", + "12 再発又は難治性多発性骨髄腫（RRMM）治験参加者を対象にmezigdomide、カルフィルゾ... 無作為化比較 非盲検 \n", + "13 未治療多発性骨髄腫を対象とした自家末梢血幹細胞移植後の地固め療法としてのIsatuximab... 単一群 非盲検 \n", + "14 再発及び難治性の多発性骨髄腫の被験者でのCC-93269の安全性及び忍容性を評価する。 単一群 非盲検 \n", + "15 神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全... 単一群 非盲検 \n", + "16 新たに診断された多発性骨髄腫（NDMM）患者を対象として、自家幹細胞移植（ASCT）後のレナ... 無作為化比較 非盲検 \n", + "17 パート 1：3ライン以上の前治療を受けた（4L+）再発・難治性多発性骨髄腫（RRMM）患者を... 無作為化比較 非盲検 \n", + "18 ・本治験の第I相用量漸増パート：再発又は難治性MM患者を対象に、単剤療法としてのREGN54... 非無作為化比較 非盲検 \n", + "19 初発IDH野生型低悪性度神経膠腫を対象に、放���線化学療法後のテモゾロミド維持療法期における交... 単一群 非盲検 \n", + "20 ウイルス感染疾患が疑われる患者について、検体を採取し、本診断法により①単純ヘルペスウイルス1... \n", + "21 本治験は、先行する第I、II及びIII相試験完了後も引き続きイサツキシマブに基づく治療による... 単一群 非盲検 \n", + "22 BRAF融合遺伝子または遺伝子再構成陽性の切除不能または再発の低悪性度神経膠腫（コホート A... 単一群 非盲検 \n", + "23 本試験の目的は，teclistamabの有効性をPVd/Kdと比較することである。 無作為化比較 非盲検 \n", + "24 本治験のパート 1 では多発性骨髄腫（MM）患者を対象として，エルラナタマブとダラツムマブお... 無作為化比較 非盲検 \n", + "25 無増悪生存期間（PFS）及び持続的微小残存病変（MRD）陰性complete respons... 無作為化比較 非盲検 \n", + "26 再発又は難治性多発性骨髄腫患者を対象にポマリドミド-デキサメタソン（Pd），レナリドミド-デ... 単一群 非盲検 \n", + "27 この試験の目的は、ciltacabtagene autoleucel(Cilta-cel)投... 単一群 非盲検 \n", + "28 自家造血幹細胞移植後に初発多発性骨髄腫患者を対象として，PF-06863135の単剤投与がレ... 無作為化比較 非盲検 \n", + "29 BNCT(Boron Neutron Capture Therapy：ホウ素中性子捕捉療法)... 単一群 非盲検 \n", + "30 本治験の主要目的は、不適合ide-celの安全性を評価することである。 単一群 非盲検 \n", + "31 本治験の目的は，teclistamab とダラツムマブ皮下投与製剤（SC）の併用（Tec-D... 無作為化比較 非盲検 \n", + "32 既存の治療法でベネフィットが得られず、進行中又は実施予定の本剤の臨床試験に適格でなく、かつ適... 単一群 非盲検 \n", + "33 使用実態下におけるデリタクト注の悪性神経膠腫患者に対する安全性及び有効性を確認することを目的... \n", + "34 未治療の高齢者多発性骨髄腫に対する新規薬剤と自家移植を組み合わせたシークエンス治療を固定期間... 単一群 非盲検 \n", + "35 未治療多発性骨髄腫に対し、ダラツムマブ、レナリドミドおよびデキサメサゾン投与による寛解導入療... 単一群 非盲検 \n", + "36 再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び... 単一群 非盲検 \n", + "37 造血幹細胞移植が適応とならない初発の多発性骨髄腫患者において，VRd 導入療法後にJNJ-6... 無作為化比較 非盲検 \n", + "38 再発又は難治性の多発性骨髄腫（RRMM）患者を対象に無増悪生存期間（PFS）についてiber... 無作為化比較 非盲検 \n", + "39 高齢または移植拒否若年の未治療多発性骨髄腫患者に対するダラツムマブ＋メルファラン＋プレドニゾ... 無作為化比較 非盲検 \n", + "40 【第 I 相部分】\\r\\n• 骨髄腫細胞特異的抗体（ MMG49）抗原陽性の再発・難治性のM... 単一群 非盲検 \n", + "41 悪性神経膠腫患者に対する放射線照射療法によって引き起こされる認知機能低下が、メマンチン塩酸塩... 無作為化比較 二重盲検 \n", + "42 悪性脊髄神経膠腫に対する塩酸ニムスチンを用いたconvection enhanced del... 単一群 非盲検 \n", + "43 初発悪性神経膠腫において手術、放射線治療およびTemozolomideを受ける、化学療法未施... 非無作為化比較 非盲検 \n", + "44 初発悪性神経膠腫に対するVEGFR1/2由来のHLA-A*2402拘束性エピトープペプチドを... 単一群 非盲検 \n", + "\n", + " 対照 割付け 研究目的 \\\n", + "0 プラセボ対照 並行群間比較 治療 \n", + "1 実薬（治療）対照 並行群間比較 治療 \n", + "2 実薬（治療）対照 並行群間比較 治療 \n", + "3 非対照 単群比較 治療 \n", + "4 非対照 単群比較 治療 \n", + "5 無治療対照/標準治療対照 並行群間比較 治療 \n", + "6 実薬（治療）対照 並行群間比較 治療 \n", + "7 非対照 単群比較 治療 \n", + "8 非対照 並行群間比較 治療 \n", + "9 実薬（治療）対照 並行群間比較 治療 \n", + "10 実薬（治療）対照 並行群間比較 治療 \n", + "11 実薬（治療）対照 並行群間比較 治療 \n", + "12 実薬（治療）対照 単群比較 治療 \n", + "13 非対照 単群比較 治療 \n", + "14 非対照 単群比較 治療 \n", + "15 非対照 単群比較 治療 \n", + "16 実薬（治療）対照 並行群間比較 治療 \n", + "17 実薬（治療）対照 並行群間比較 治療 \n", + "18 非対照 単群比較 治療 \n", + "19 非対照 単群比較 治療 \n", + "20 \n", + "21 非対照 単群比較 治療 \n", + "22 非対照 単群比較 治療 \n", + "23 実薬（治療）対照 並行群間比較 治療 \n", + "24 実薬（治療）対照 要因分析 治療 \n", + "25 実薬（治療）対照 並行群間比較 治療 \n", + "26 非対照 単群比較 治療 \n", + "27 非対照 単群比較 その他 \n", + "28 実薬（治療）対照 並行群間比較 治療 \n", + "29 非対照 単群比較 その他 \n", + "30 非対照 単群比較 治療 \n", + "31 実薬（治療）対照 並行群間比較 治療 \n", + "32 非対照 単群比較 治療 \n", + "33 \n", + "34 非対照 単群比較 治療 \n", + "35 非対照 単群比較 治療 \n", + "36 非対照 単群比較 治療 \n", + "37 実薬（治療）対照 並行群間比較 治療 \n", + "38 実薬（治療）対照 並行群間比較 治療 \n", + "39 実薬（治療）対照 並行群間比較 治療 \n", + "40 非対照 単群比較 治療 \n", + "41 プラセボ対照 並行群間比較 治療 \n", + "42 無治療対照/標準治療対照 単群比較 治療 \n", + "43 非対照 単群比較 治療 \n", + "44 ヒストリカルコントロール 単群比較 治療 \n", + "\n", + " 主たる選択基準 \\\n", + "0 1.\\t治験の手順を理解し、（被験者又は法定代理人による）書面によるインフォームドコンセント... \n", + "1 以下の基準をすべて満たす必要がある
\\r\\n‐生検によって、以下に示す2016 年WH... \n", + "2 一次登録適格規準
\\r\\n(1)　登録前に実施した最新の手術時の術中迅速病理診断もしく... \n", + "3 米国東海岸がん臨床試験グループ（ECOG）のパフォーマンススコアが2以下
\\r\\n3～... \n", + "4 - 治験依頼者が実施するサバトリマブの試験に登録されて，サバトリマブの投与を受けており，なお... \n", + "5 1）\\t登録前直近の病理診断により組織学的にWHO2021に基づく悪性神経膠腫（膠芽腫または... \n", + "6 ・国際骨髄腫作業部会（IMWG）診断規準に従って多発性骨髄腫の診断を受けている。
\\r... \n", + "7 - 18 歳以上又は治験が実施される管轄区域における同意の法定年齢以上の方。
\\n\\n... \n", + "8 ・過去に1回以上の前治療歴を有する、再発・難治性多発性骨髄腫患者
\\r\\n・Easte... \n", + "9 ・IMWG規準で定義される多発性骨髄腫と診断を受け，過去に抗CD38抗体およびレナリドミドを... \n", + "10 ・導入療法後に大量化学療法及びASCTを受けたが、その後地固め療法又は維持療法を受けていない... \n", + "11 1. 多発性骨髄腫の診断が記録されており、以下のいずれかの定義を満たす測定可能病変を有する被... \n", + "12 多発性骨髄腫の診断が記録されており、測定可能病変を有する。
\\r\\n1レジメン以上の抗... \n", + "13 1)同意取得時の年齢が20歳以上、70歳未満の患者（性別及び入院・外来を問わず）
\\r... \n", + "14 ・再発及び難治性の多発性骨髄腫の病歴があること。
\\r\\n・米国東海岸癌臨床試験グルー... \n", + "15 ＜コホート1＞以下のすべての項⽬を満たすものとする。
\\r\\n1）摘出術⼜は⽣検の病理... \n", + "16 -症候性多発性骨髄腫(MM)の確定診断を受けている
\\r\\n- 米国東海岸癌臨床試験グ... \n", + "17 • 署名時の年齢が18歳以上、又は各国における同意可能な法定年齢以上である被験者。
\\... \n", + "18 ・米国東海岸がん臨床試験グループ（ECOG）パフォーマンスステータスが1以下の被験者
... \n", + "19 1）腫瘍摘出術または生検術を行い、IDH 野生型神経膠腫（グレードⅢ）（退形成性星細胞腫）＊... \n", + "20 ウイルス感染症が疑われるもの（造血幹細胞移植＜自家骨髄移植、自家末梢血幹細胞移植、同種骨髄移... \n", + "21 - 同意書への署名の時点で18歳以上（又は治験を実施する管轄区域の同意の法定成人年齢以上）の... \n", + "22 コホートA、コホートB共通の適格規準
\\r\\n1）\\t保険診療下で行われているNGSを... \n", + "23 ・以下の基準により定義される多発性骨髄腫が診断されている。
\\r\\na. 国際骨髄腫作... \n", + "24 ・IMWG規準(Rajkumar et al., 2014)で定義される多発性骨髄腫と診断を... \n", + "25 ・IMWGの診断基準に従いNDMMと確定診断されており，初期治療計画の一部として大量療法及び... \n", + "26 - 米国東海岸がん臨床試験グループ（ECOG）performanceが2以下である。
... \n", + "27 ・企業が主導（共同）して実施する臨床試験でcilta-celの投与を少なくとも1回受けた被験... \n", + "28 選択基準:
\\r\\n•IMWG 規準で定義される多発性骨髄腫と診断を受けた患者。初発多... \n", + "29 ① 悪性神経膠腫の病理組織学的診断が得られている。
\\r\\n② 標準治療後に再発し、ベ... \n", + "30 1.治験開始前に、同意説明文書の内容を理解し、自由意思により署名できる被験者及び／又はLAR... \n", + "31 選択基準
\\r\\n‐以下の基準により定義される多発性骨髄腫が確認されている。\\n\\r\\... \n", + "32 -国際骨髄腫作業部会(IMWG)の基準[Rajkumar, 2014]に従って組織学的又は細... \n", + "33 ・本品投与群：登録期間内に本剤の投与を開始する全ての患者
\\r\\n・対照群：本品納入施... \n", + "34 1) 登録時の年齢が66歳以上75歳以下で、fitの患者。
\\r\\n2) IMWG... \n", + "35 1) 登録時の年齢が20歳以上65歳以下の症例。
\\r\\n2) IMWGの診断基準... \n", + "36 1.\\t3ヵ月以上の生存が見込める患者
\\r\\n2.\\t前治療（化学療法、手術又は放射... \n", + "37 ･国際骨髄腫作業部会(IMWG )診断規準によるMMの診断が確定している被験者。
\\r... \n", + "38 1. MMの診断がされており測定可能病変（以下の基準のいずれかに該当する場合と定義）を有する... \n", + "39 一次登録適格規準
\\r\\n（1）IMWG2014の診断規準のMyeloma defin... \n", + "40 -同意取得時の年齢が20歳以上，80歳（第 I 相部分では75歳）以下の患者
\\r\\n... \n", + "41 1.　神経放射線学的及び病理組織学的診断法を用いWHO (World Health Orga... \n", + "42 1.\\t臨床的に脊髄再発神経膠腫と考えられる症例。放射線画像診断的には、脊髄髄内に病変を有す... \n", + "43 悪性神経膠腫において、これから放射線療法を受ける、化学療法未施行症例に対し、WT1-W10ペ... \n", + "44 1）悪性神経膠腫
\\r\\n2）HLA型がHLA-A*2402、A*0201、A*02... \n", + "\n", + " 主たる除外基準 ... purpose \\\n", + "0 1.\\t原発性脊椎腫瘍。\\n\\r\\n2.\\tびまん性内在性橋神経膠腫（DIPG）。DIPGは... ... treatment purpose \n", + "1 以下の基準のいずれかに該当する場合、本治験へ参加できない。\\n\\r\\n‐びまん性橋膠腫（di... ... treatment purpose \n", + "2 (1)　活動性の重複がんを有する（同時性重複がん/多発がんおよび無病期間が2年以内の異時性重... ... treatment purpose \n", + "3 B細胞成熟抗原（BCMA）xCD3二重特異性抗体の投与歴がある。\\n ... treatment purpose \n", + "4 - 親試験でサバトリマブの投与を受けていないコホート又は投与群の患者。\\n\\r\\n- 許容で... ... treatment purpose \n", + "5 1）\\t登録前2年以内の他の悪性腫瘍の既往または合併を有する。ただし局所治療により治癒と判断... ... treatment purpose \n", + "6 ・多発性骨髄腫又はくすぶり型骨髄腫に対して，短期的コルチコステロイド投与\\n\\r\\n（デキサ... ... treatment purpose \n", + "7 - 多発性骨髄腫の中枢神経系への浸潤を示す臨床徴候が認められる方。\\n\\n\\n\\r\\n- 慢... ... treatment purpose \n", + "8 ・治験実施計画書��規定された入院及び活動制限を遵守できない。\\n\\r\\n・同種幹細胞移植（S... ... treatment purpose \n", + "9 ・くすぶり型多発性骨髄腫を有する患者\\n\\r\\n・形質細胞白血病を有する患者\\n\\r\\n・ア... ... treatment purpose \n", + "10 ・中枢神経系（CNS）に骨髄腫病変を有する又は既往歴のある治験参加者\\n\\r\\n・非分泌型M... ... treatment purpose \n", + "11 1. プロテアソーム阻害剤の投与期間中又は最終投与後60日以内に病勢進行が確認された被験者。... ... treatment purpose \n", + "12 Mezigdomide又はカルフィルゾミブによる前治療歴を有する治験参加者。\\n\\r\\n前治... ... treatment purpose \n", + "13 1)アミロイドーシスによる症状があり、アミロイド沈着が組織学的に証明された症例\\n\\r\\n2... ... treatment purpose \n", + "14 ・症候性の中枢神経系浸潤を有する多発性骨髄腫患者\\n\\r\\n・CC-93269投与開始前3ヵ... ... treatment purpose \n", + "15 ＜コホート1、コホート2共通＞\\n\\r\\n1） 活動性の重複がんを有する（同時性重複がん/多... ... treatment purpose \n", + "16 -地固め療法の有無に関わらずASCT後にprogressive disease又は臨床的再発... ... treatment purpose \n", + "17 • 原発性ALアミロイドーシス、活動性POEMS症候群、原発性形質細胞性白血病と診断されてい... ... treatment purpose \n", + "18 ・形質細胞白血病、原発性全身性軽鎖アミロイドーシス（骨髄腫関連アミロイドーシスを除く）、ヴァ... ... treatment purpose \n", + "19 以下のいずれかの条件に該当する者は対象としない。\\n\\r\\n1) 活動性の重複がんを有する（... ... treatment purpose \n", + "20 検体採取の同意が得られない患者、試験の担当医師が不適当と判断した患者は対象として除外する。こ... ... \n", + "21 以下のいずれかの基準に該当する場合は、治験の組入れ対象から除外する。\\n\\r\\n- 先行試験... ... treatment purpose \n", + "22 1）\\t活動性の重複がんを有する（ただし、次の①～③は除外しない：①完全切除された以下のがん... ... treatment purpose \n", + "23 ・B 細胞成熟抗原（BCMA）を標的とする前治療を受けていた。\\n\\r\\n・以下が認められる... ... treatment purpose \n", + "24 ・くすぶり型多発性骨髄腫\\n\\r\\n・意義不明の単クローン性免疫グロブリン血症\\n\\r\\n・... ... treatment purpose \n", + "25 ・標的を問わずCAR-T療法による前治療。\\n\\r\\n・BCMAを標的とする全ての治療歴。\\... ... treatment purpose \n", + "26 - 治験薬の初回投与前12 週間以内に末梢血自家幹細胞移植を受けている，又は治験薬の初回投与... ... treatment purpose \n", + "27 なし ... other \n", + "28 除外基準:\\n\\r\\n•形質細胞白血病\\n\\r\\n•アミロイドーシス，ワルデンシュトレームマ... ... treatment purpose \n", + "29 ① 髄腔播種を認める。\\n\\r\\n② 抗生物質、抗ウイルス薬、抗真菌薬などの静脈内投与が必要... ... other \n", + "30 1.有効成分又は添加剤に対して過敏症のある患者。\\n\\r\\n2.担当医師の判断で、LD化学療... ... treatment purpose \n", + "31 除外基準\\n\\r\\n‐治験薬又はその添加物に対する禁忌又は生命を脅かすアレルギー，過敏症を呈... ... treatment purpose \n", + "32 -同種幹細胞移植歴を有する被験者\\n\\r\\n-腎疾患、肝疾患、心血管障害、悪性腫瘍を含む、重... ... treatment purpose \n", + "33 なし ... \n", + "34 1) くすぶり型およびIgM型の骨髄腫、孤立性形質細胞腫、形質細胞性白血病、POEMS症候... ... treatment purpose \n", + "35 1) くすぶり型およびIgM型の骨髄腫、孤立性形質細胞腫、形質細胞性白血病、POEMS症候... ... treatment purpose \n", + "36 1.\\tDay 1前の3ヵ月以内にベバシズマブ又はその他の血管内皮増殖因子（VEGF）阻害薬... ... treatment purpose \n", + "37 ･Myeloma Geriatric Assessmentスコアに従ったフレイル指数が2点以... ... treatment purpose \n", + "38 1. 以下の臨床検査値異常のいずれかが認められる\\n\\r\\na. 好中球絶対数（ANC）が1... ... treatment purpose \n", + "39 （1）活動性の重複がんを有する（同時性重複がん/多発がんおよび無病期間が5年以内��異時性重複... ... treatment purpose \n", + "40 -次治療で造血幹細胞移植併用大量化学療法を予定している患者\\n\\r\\n-他の活動性の重複がん... ... treatment purpose \n", + "41 1．試験薬に対して過敏症のある患者\\n\\r\\n2．腎機能障害のある患者\\n\\r\\n3．尿pH... ... treatment purpose \n", + "42 1)\\t活動性の重複がんを有する\\n\\r\\n2)\\t治療が必要な髄膜炎または肺炎を合併\\n\\... ... treatment purpose \n", + "43 1）コントロール不良な感染症（活動性の結核を含む）を有する患者。\\n\\r\\n2）重篤な合併症... ... treatment purpose \n", + "44 1)コントロール不良な感染症を有する患者。 \\n\\r\\n2）重篤な合併症を有する患者。 \\n... ... treatment purpose \n", + "\n", + " Inclusion Criteria \\\n", + "0 1. Able to understand the study procedures and... \n", + "1 Subjects required to meet all the folloiwng cr... \n", + "2 The first registration criteria\\n\\r\\n(1) The m... \n", + "3 Eastern Cooperative Oncology Group (ECOG) perf... \n", + "4 - Participant is currently enrolled in a Novar... \n", + "5 1) Histologically diagnosed as high grade glio... \n", + "6 '- Have a diagnosis of multiple myeloma accord... \n", + "7 - Participants must be at least 18 years of ag... \n", + "8 -Participants with R/R MM who have received at... \n", + "9 * Prior diagnosis of multiple myeloma as defin... \n", + "10 -Participants aged >=18 with Newly Diagnose... \n", + "11 1. Participant has documented diagnosis of mul... \n", + "12 Participant has documented diagnosis of Multip... \n", + "13 1)Patients aged between 20 and less than 70 up... \n", + "14 -History of multiple myeloma with relapsed and... \n", + "15 <Cohort 1>\\n\\r\\n All of the following it... \n", + "16 - Confirmed diagnosis of symptomatic multiple ... \n", + "17 -Participants at the time of signing the Infor... \n", + "18 - Eastern Cooperative Oncology Group (ECOG) pe... \n", + "19 At the time of enrollment, patients will be in... \n", + "20 Thing with suspected virus infection(limited t... \n", + "21 - Participant must be >=18 years of age (or... \n", + "22 Inclusion criteria for both cohort A and B\\n\\r... \n", + "23 - Documented diagnosis of multiple myeloma as ... \n", + "24 Inclusion Criteria:\\n\\r\\n*Diagnosis of multipl... \n", + "25 - Participants with documented NDMM accordin... \n", + "26 - Eastern Cooperative Oncology Group (ECOG) pe... \n", + "27 - Participants who have received at least one ... \n", + "28 Inclusion Criteria:\\n\\r\\n*Diagnosis of MM as d... \n", + "29 1. A histopathological diagnosis of malignant ... \n", + "30 1.Subject and/or LAR must understand and volun... \n", + "31 Inclusion Criteria:\\n\\r\\n- Documented multiple... \n", + "32 -Histologically or cytologically confirmed dia... \n", + "33 -Delytact injection group : All patients who s... \n", + "34 1) Patients who are 66 years old or older and ... \n", + "35 1) Cases in which the age at the time of regis... \n", + "36 1.\\tEstimated life expectancy >= 3 months\\n... \n", + "37 - Documented diagnosis of multiple myeloma (MM... \n", + "38 1. Documented diagnosis of MM and measurable d... \n", + "39 First registration criteria\\n\\r\\n(1)At leaset ... \n", + "40 -Patients aged between 20 and 80 (75 for the p... \n", + "41 Patients with malignant glioma who are classif... \n", + "42 1. Clinically considered a spinal cord recurre... \n", + "43 Malignant glioma patients who are going to rec... \n", + "44 1)malignant glioma \\n\\r\\n2) HLA-A*2402, A*0201... \n", + "\n", + " Exclusion Criteria \\\n", + "0 1. Primary spinal tumor.\\n\\r\\n2. Diffuse intri... \n", + "1 Patients who meets any of the following criter... \n", + "2 (1) Synchronous or metachronous (within 2 year... \n", + "3 Received B-cell maturation antigen (BCMA)xCD3 ... \n", + "4 - Participants in cohorts or treatment groups ... \n", + "5 1) Have a history or merger of other malignanc... \n", + "6 - Received any prior therapy for multiple myel... \n", + "7 - Participants exhibiting clinical signs of ce... \n", + "8 -Inability to comply with protocol-mandated ho... \n", + "9 * Smoldering multiple myeloma.\\n\\r\\n* Plasma c... \n", + "10 -Participant with known central nervous system... \n", + "11 1. Participant has had progression during trea... \n", + "12 Participant who has had prior treatment with m... \n", + "13 1) Patients with symptoms due to amyloidosis a... \n", + "14 -Symptomatic central nervous system involvemen... \n", + "15 <Common to Cohort 1 and Cohort 2>\\n\\r\\n1... \n", + "16 - Progressive disease or clinical relapse (as ... \n", + "17 - Diagnosis of primary Amyloid Light chain (AL... \n", + "18 - Diagnosis of plasma cell leukemia, primary s... \n", + "19 Any of the following conditions shall not appl... \n", + "20 The patients who judged that the patients that... \n", + "21 Participants are excluded from the study if an... \n", + "22 1) Active double primary cancer (but not (1)-(... \n", + "23 - Received any prior B cell maturation antigen... \n", + "24 Exclusion Criteria:\\n\\r\\n*Smoldering Multiple ... \n", + "25 - Prior treatment with CAR-T therapy directed ... \n", + "26 - Received a peripheral autologous stem cell t... \n", + "27 N/A \n", + "28 Exclusion Criteria:\\n\\r\\n*Plasma cell leukemia... \n", + "29 Patients with the following medical conditions... \n", + "30 1. Subject has a hypersensitivity to the activ... \n", + "31 Exclusion Criteria:\\n\\r\\n- Contraindications o... \n", + "32 -Prior allogenic stem cell transplant.\\n\\r\\n-A... \n", + "33 none \n", + "34 1) Cases of smoldering and IgM myeloma, solita... \n", + "35 1) Cases of smoldering and IgM myeloma, solita... \n", + "36 1.\\tPrior therapy with bevacizumab or other an... \n", + "37 -Frailty index of >=2 according to Myeloma ... \n", + "38 1. Any of the following laboratory abnormaliti... \n", + "39 (1) Simultaneous or metachronous (within 5 yea... \n", + "40 -Patients who are scheduled to receive high-do... \n", + "41 1. Patients with hypersensitivity to the study... \n", + "42 1) have active duplicate cancer\\n\\r\\n2) Mergin... \n", + "43 1)\\tPatients with uncontrollable infectious di... \n", + "44 1) Uncontrollable severe infectious diseases. ... \n", + "\n", + " Age Minimum Age Maximum Gender \\\n", + "0 No limit No limit \n", + "1 No limit 21age old not \n", + "2 18age old over No limit Both \n", + "3 18age old over No limit \n", + "4 18age old over No limit Both \n", + "5 18age old over 75age old under Both \n", + "6 18age old over No limit Both \n", + "7 18age old over No limit Both \n", + "8 18age old over No limit Both \n", + "9 18age old over No limit Both \n", + "10 18age old over No limit Both \n", + "11 18age old over No limit Both \n", + "12 18age old over No limit Both \n", + "13 20age old over 70age old not Both \n", + "14 18age old over No limit Both \n", + "15 18age old over No limit Both \n", + "16 18age old over No limit Both \n", + "17 18age old over No limit Both \n", + "18 18age old over No limit Both \n", + "19 18age old over No limit Both \n", + "20 No limit No limit Both \n", + "21 18age old over No limit Both \n", + "22 12age old over No limit Both \n", + "23 18age old over No limit Both \n", + "24 18age old over No limit Both \n", + "25 18age old over No limit Both \n", + "26 20age old over No limit Both \n", + "27 18age old over No limit Both \n", + "28 18age old over No limit Both \n", + "29 20age 0month 0week old over 79age 0month 0week old under Both \n", + "30 18age old over No limit Both \n", + "31 18age old over No limit Both \n", + "32 18age old over No limit Both \n", + "33 No limit No limit Both \n", + "34 66age old over 75age old under Both \n", + "35 20age old over 65age old under Both \n", + "36 18age old over No limit Both \n", + "37 20age old over No limit Both \n", + "38 18age old over No limit Both \n", + "39 20age old over No limit Both \n", + "40 20age old over 80age old under Both \n", + "41 20age old over No limit Both \n", + "42 15age old over 75age old under Both \n", + "43 18age old over 80age old not Both \n", + "44 16age old over 79age old under Both \n", + "\n", + " Discontinuation Criteria \\\n", + "0 None \n", + "1 None \n", + "2 None \n", + "3 None \n", + "4 None \n", + "5 None \n", + "6 None \n", + "7 None \n", + "8 None \n", + "9 None \n", + "10 None \n", + "11 None \n", + "12 None \n", + "13 None \n", + "14 None \n", + "15 None \n", + "16 None \n", + "17 None \n", + "18 None \n", + "19 None \n", + "20 None \n", + "21 None \n", + "22 None \n", + "23 None \n", + "24 None \n", + "25 None \n", + "26 None \n", + "27 None \n", + "28 None \n", + "29 None \n", + "30 None \n", + "31 None \n", + "32 None \n", + "33 None \n", + "34 None \n", + "35 None \n", + "36 None \n", + "37 None \n", + "38 None \n", + "39 None \n", + "40 None \n", + "41 None \n", + "42 None \n", + "43 None \n", + "44 None \n", + "\n", + " Keyword \\\n", + "0 \n", + "1 \n", + "2 \n", + "3 \n", + "4 \n", + "5 glioblastoma, grade3/4 astrocytoma, grade3 oli... \n", + "6 \n", + "7 \n", + "8 \n", + "9 \n", + "10 \n", + "11 \n", + "12 \n", + "13 \n", + "14 \n", + "15 \n", + "16 \n", + "17 \n", + "18 \n", + "19 Glioma \n", + "20 Leukemia, malignant lymphoma, multiple myeloma... \n", + "21 \n", + "22 BRAF fusion gene, BRAF rearrangement, low-grad... \n", + "23 \n", + "24 \n", + "25 \n", + "26 \n", + "27 \n", + "28 \n", + "29 \n", + "30 \n", + "31 \n", + "32 \n", + "33 \n", + "34 \n", + "35 \n", + "36 \n", + "37 \n", + "38 \n", + "39 \n", + "40 \n", + "41 gliobalastoma, anaplastic astrocytoma,anaplast... \n", + "42 Spinal cord tumor \n", + "43 \n", + "44 Malignant glioma \n", + "\n", + " Intervention(s) Study Type \n", + "0 Participants will be randomized at baseline in... NaN \n", + "1 Drug: Abemaciclib\\n\\r\\nAdministered orally\\n\\r... NaN \n", + "2 Group A: Standard treatment group [Adjuvant ch... Interventional \n", + "3 Experimental: ABBV-383 Dose A\\n\\r\\nParticipant... NaN \n", + "4 Sabatolimab (MBG453): Solution for intravenous... NaN \n", + "5 Group A: BPC Therapy\\n\\r\\nDepending on the pat... NaN \n", + "6 Teclistamab-Teclistamab, Daratumumab SC, Lenal... NaN \n", + "7 AZD0305 IV every 3 weeks\\n NaN \n", + "8 cevostamab: Cevostamab will be administered in... NaN \n", + "9 Drug: Elranatamab\\n\\r\\nElranatamab will be adm... NaN \n", + "10 ArmA\\n\\r\\nBiological: idecabtagene vicleucel\\n... NaN \n", + "11 [Japan safety lead-in cohort]\\n\\r\\nMezigdomide... NaN \n", + "12 Arm A: Mezigdomide, Carfilzomib and Dexamethas... NaN \n", + "13 Study treatment,Autologous Peripheral Blood St... NaN \n", + "14 CC-93269 NaN \n", + "15 <cohort1>\\n\\r\\nLomustine 130 mg/m2 orall... NaN \n", + "16 Arm A1: Iberdomide Dose 1\\n\\r\\nArm A2: Iberdom... NaN \n", + "17 Part1:\\n\\r\\nDrug: Belantamab\\n\\r\\nDrug: Belant... NaN \n", + "18 Drug: REGN5458 administered by intravenous (IV... NaN \n", + "19 The patient using the product should shave all... NaN \n", + "20 Observational \n", + "21 Drug: Isatuximab IV (SAR650984)\\n\\r\\n Pharmace... NaN \n", + "22 Binimetinib is administered 45 mg orally, twic... NaN \n", + "23 Teclistamab: Participants will receive teclist... NaN \n", + "24 Part 1 Dose Level 1:Elranatamab, Daratumumab, ... NaN \n", + "25 - Arm A (DVRd Induction + ASCT + DVRd Consolid... NaN \n", + "26 Participants will receive intravenous (IV) ABB... NaN \n", + "27 Cilta-cel:Participants who had received cilta-... NaN \n", + "28 Drug: Elranatamab \\n\\r\\nBCMA-CD3 bispecific an... NaN \n", + "29 BNCT is performed in combination with a cyclot... Interventional \n", + "30 In accordance with the ide-cel prescribing inf... NaN \n", + "31 Daratumumab\\n\\r\\nArm A: Teclistamab-daratumuma... NaN \n", + "32 Belantamab mafodotin (anti-BCMA (B-cell matura... NaN \n", + "33 NaN \n", + "34 1. Daratumumab + lenalidomide + dexamethasone ... Interventional \n", + "35 1) Induction therapy\\n\\r\\nDRD therapy 1,2 cour... Interventional \n", + "36 Patients will receive DSP-0390 orally once dai... NaN \n", + "37 Arm A\\n\\r\\nParticipants will receive bortezomi... NaN \n", + "38 [IberDd] At the First Stage, Iberdomide (CC-22... NaN \n", + "39 Induction therapy (both arm A and arm B) D-MPB... Interventional \n", + "40 OPC-415 (up to 1X10^7cells/kg)\\n\\r\\nOn 2 days\\... NaN \n", + "41 1)Arm A: Patients randomly selected group have... Interventional \n", + "42 ACNU delivery (0.25 mg/ml, 4ml) into the spin... Interventional \n", + "43 1)\\tWT1-W10 peptide immunotherapy\\n\\r\\nIntrade... Interventional \n", + "44 Subcutaneous injection of VEGFR1 and VEGFR2 pe... Interventional \n", + "\n", + "[45 rows x 32 columns]" + ] + }, + "execution_count": 20, + "metadata": {}, + "output_type": "execute_result" + } + ], + "source": [ + "sorted_df" + ] + }, + { + "cell_type": "code", + "execution_count": null, + "metadata": {}, + "outputs": [], + "source": [] + } + ], + "metadata": { + "kernelspec": { + "display_name": "gradio", + "language": "python", + "name": "python3" + }, + "language_info": { + "codemirror_mode": { + "name": "ipython", + "version": 3 + }, + "file_extension": ".py", + "mimetype": "text/x-python", + "name": "python", + "nbconvert_exporter": "python", + "pygments_lexer": "ipython3", + "version": "3.12.3" + } + }, + "nbformat": 4, + "nbformat_minor": 2 +}